ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Bio Rad Laboratories Inc

Bio Rad Laboratories Inc (BIO)

279.73
-1.29
(-0.46%)
Closed April 21 4:00PM
279.73
0.00
(0.00%)
After Hours: 7:23PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
279.73
Bid
-
Ask
-
Volume
294,125
276.24 Day's Range 285.27
261.59 52 Week Range 489.355
Market Cap
Previous Close
281.02
Open
283.12
Last Trade
30741
@
279.73
Last Trade Time
Financial Volume
$ 82,410,946
VWAP
280.1902
Average Volume (3m)
205,952
Shares Outstanding
28,518,436
Dividend Yield
-
PE Ratio
-12.53
Earnings Per Share (EPS)
-22.35
Revenue
2.67B
Net Profit
-637.32M

About Bio Rad Laboratories Inc

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for c... Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bio Rad Laboratories Inc is listed in the Lab Analytical Instruments sector of the New York Stock Exchange with ticker BIO. The last closing price for Bio Rad Laboratories was $281.02. Over the last year, Bio Rad Laboratories shares have traded in a share price range of $ 261.59 to $ 489.355.

Bio Rad Laboratories currently has 28,518,436 shares outstanding. The market capitalization of Bio Rad Laboratories is $7.98 billion. Bio Rad Laboratories has a price to earnings ratio (PE ratio) of -12.53.

Bio Rad Laboratories (BIO) Options Flow Summary

Overall Flow

Bearish

Net Premium

-295k

Calls / Puts

0.00%

Buys / Sells

50.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

BIO Latest News

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on...

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option...

Bio-Rad’s Chief Operating Officer Andrew Last to Retire

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and...

Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its...

Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s management will participate in a...

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full...

Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year...

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced that Norman Schwartz, President and CEO, and Andrew...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-29.33-9.49006665372309.06311.97268.916241646291.4889908CS
4-74.34-20.9958482786354.07360.13268.916199681320.62096869CS
12-50.27-15.2333333333330364.24268.916205952329.21016819CS
26-38.11-11.9903095897317.84364.24261.59246071313.77846548CS
52-196.71-41.2874653681476.44489.355261.59224217345.22410871CS
156-346.39-55.3232607168626.12832.7261.59188328469.43329836CS
260-13.27-4.52901023891293832.7261.59199640456.37666103CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

BIO Discussion

View Posts
PirateGary PirateGary 4 years ago
Offering 16M @ .41 for the CV
👍️0
Penny Roger$ Penny Roger$ 12 years ago
~ Tuesday! $BIO ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BIO ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BIO&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BIO&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=BIO
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BIO#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BIO+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BIO
Finviz: http://finviz.com/quote.ashx?t=BIO
~ BusyStock: http://busystock.com/i.php?s=BIO&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=BIO >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
Penny Roger$ Penny Roger$ 12 years ago
<<< $BIO Links! >>> ~ MAC's Quick DD Links without the charts.



Open these links (or the ones you desire) in background tabs
http://help.opera.com/Linux/9.52/en/keyboard.html
http://lifehacker.com/263940/force-links-to-open-in-the-background


PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/BIO


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/BIO/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/BIO/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/BIO/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/BIO/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/BIO/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/BIO/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/BIO/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/BIO/research


Google Finance Summary ~ http://www.google.com/finance?q=BIO
Google Finance News ~ http://www.google.com/finance/company_news?q=BIO
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=BIO
Google Finance Financials ~ http://www.google.com/finance?q=BIO&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=BIO
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=BIO&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=BIO+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=BIO+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=BIO+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=BIO
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=BIO+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=BIO+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/BIO
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/BIO
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=BIO+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=BIO+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=BIO+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=BIO+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=BIO+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=BIO+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=BIO+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=BIO+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=BIO+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=BIO+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=BIO+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=BIO&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=BIO
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=BIO
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=BIO
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=BIO
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=BIO
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=BIO&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=BIO&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/BIO?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/BIO
Barchart Options Quotes ~ http://barchart.com/options/stocks/BIO
Barchart Technical Chart ~ http://barchart.com/charts/stocks/BIO&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/BIO&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/BIO
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=BIO
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/BIO
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/BIO
Barchart News Headlines ~ http://barchart.com/news/stocks/BIO
Barchart Profile ~ http://barchart.com/profile//BIO
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=BIO&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=BIO&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=BIO&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=BIO&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/BIO/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/BIO/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/BIO/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/BIO/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/BIO
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/BIO/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/BIO/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/BIO/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/BIO/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/BIO/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/BIO/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=BIO&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=BIO


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=BIO


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=BIO&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=BIO
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=BIO


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=BIO&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=BIO.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=BIO®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/BIO
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/BIO/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/BIO/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/BIO/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=BIO&selected=BIO
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=BIO&selected=BIO
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/BIO/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/BIO/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/BIO/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/BIO/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/BIO/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/BIO/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/BIO/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/BIO/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/BIO/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/BIO/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/BIO/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/BIO/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/BIO/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/BIO/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=BIO&selected=BIO
NASDAQ Financials ~ http://www.nasdaq.com/symbol/BIO/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/BIO/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/BIO/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/BIO/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/BIO/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/BIO/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/BIO/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/BIO/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/BIO.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/BIO/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/BIO/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/BIO/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/BIO/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/BIO/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/BIO/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=BIO


YCharts ~ http://ycharts.com/companies/BIO
YCharts Performance ~ http://ycharts.com/companies/BIO/performance
YCharts Dashboard ~ http://ycharts.com/companies/BIO/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=BIO&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=BIO&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=BIO&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=BIO


Zacks Quote ~ http://www.zacks.com/stock/quote/BIO
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=BIO
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=BIO


Knobias ~ http://knobias.10kwizard.com/files.php?sym=BIO


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=BIO


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/BIO/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=BIO&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=BIO®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=BIO®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=BIO®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=BIO®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=BIO®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=BIO


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=BIO


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=BIO&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=BIO&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=BIO
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=BIO&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=BIO


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=BIO


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=BIO


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=BIO

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=BIO
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=BIO

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=BIO

Investorpoint ~ http://www.investorpoint.com/ enter "BIO" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "BIO" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=BIO

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=BIO

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=BIO

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=BIO

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=BIO

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "BIO" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=BIO&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=BIO
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=BIO
Check those searches for recent BIO mentions. If BIO is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks
👍️0
Penny Roger$ Penny Roger$ 12 years ago
~ Thursday! $BIO ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BIO ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BIO&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BIO&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=BIO
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BIO#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BIO+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BIO
Finviz: http://finviz.com/quote.ashx?t=BIO
~ BusyStock: http://busystock.com/i.php?s=BIO&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=BIO >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
SAE SAE 12 years ago
Bio-Rad Reports Third-Quarter Revenue Growth of More Than 9 Percent

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2011.

Third-quarter reported revenues were $516.5 million, up 9.5% compared to $471.5 million reported for the third quarter of 2010. On a currency-neutral basis, quarterly revenues increased 1.1% compared to the same period last year. Third-quarter gross margin increased to 57.3%, compared to 56.5% during the same quarter in 2010.

Net income attributable to Bio-Rad for the third quarter was $45.9 million, or $1.61 per share on a fully diluted basis versus $1.59 per share reported for the same period last year.

Year-to-date revenues grew by 9.3% to $1.5 billion compared to $1.4 billion for the first three quarters of 2010. Adjusting for the impact of currency, revenue growth was 3.4%.

Year-to-date net income attributable to Bio-Rad for 2011 was $119.0 million, or $4.18 per share on a fully diluted basis compared to $117.6 million, or $4.18 per share during the same period in 2010.

"While performance in the third-quarter shows good momentum and growth in many of our core product areas, we are feeling the impact of an uncertain economic environment in many of our markets abroad," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "As we wrap up the year, we will carefully monitor these pressures on our global operation and look for new opportunities to grow our business."

Life Science

The Life Science segment net sales for the third quarter were $171.5 million, up 11.9% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 5.1% compared to the third quarter of 2010. These results reflect strength of the segment's electrophoresis and imaging product lines, which showed solid growth during the third quarter. Performance was also bolstered by the Company's amplification products, several new product launches, as well as assays for the Bio-Plex® suspension array system, which can analyze up to 100 biomolecules in a single patient sample.

Clinical Diagnostics

Reported net sales for the Clinical Diagnostics segment in the third quarter rose to $341.3 million, up 8.4% compared to the same quarter last year. On a currency-neutral basis, sales were down 0.9%. Overall performance of the Clinical Diagnostics segment was negatively affected by economic challenges impacting worldwide healthcare markets, partially offset by continuing growth of our quality controls and BioPlex® 2200 product lines. In July, the Company announced that it had received FDA Premarket Application approval from the FDA for its fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme immunoassay). The new assay detects both HIV antigens and HIV antibodies, offering earlier detection of HIV infections, including acute HIV infections.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 1, 2011. Interested parties may access the call by dialing 800-322-5044 (in the U.S.) or 617-614-4927 (international), access number 51248028.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 19666335, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.



Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income

(in thousands, except per share data)
(UNAUDITED)


Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ------------------------
2011 2010 2011 2010
----------- ----------- ----------- -----------
Net sales $ 516,514 $ 471,502 $ 1,523,291 $ 1,393,398
Cost of goods sold 220,338 205,172 656,368 601,633
----------- ----------- ----------- -----------
Gross profit 296,176 266,330 866,923 791,765

Selling, general and
administrative
expense 176,867 148,654 521,370 458,541
Research and
development expense 45,387 42,874 136,327 126,999
----------- ----------- ----------- -----------
Income from operations 73,922 74,802 209,226 206,225

Interest expense 12,341 14,400 41,148 43,169
Foreign exchange
losses, net 6,346 2,749 12,132 3,546
Other (income)
expense, net (538) (256) (5,907) (3,572)
----------- ----------- ----------- -----------
Income before income
taxes 55,773 57,909 161,853 163,082

Provision for income
taxes (9,911) (12,824) (43,031) (44,084)
----------- ----------- ----------- -----------
Net income including
noncontrolling
interests 45,862 45,085 118,822 118,998

Net loss (income)
attributable to
noncontrolling
interests 35 (321) 162 (1,416)
----------- ----------- ----------- -----------
Net income attributable
to Bio-Rad $ 45,897 $ 44,764 $ 118,984 $ 117,582
=========== =========== =========== ===========

Basic earnings per
share:
Net income per share
basic attributable to
Bio-Rad $ 1.63 $ 1.62 $ 4.25 $ 4.26
=========== =========== =========== ===========

Weighted average
common shares - basic 28,072 27,697 27,997 27,616
=========== =========== =========== ===========

Diluted earnings per
share:
Net income per share
diluted attributable
to Bio-Rad $ 1.61 $ 1.59 $ 4.18 $ 4.18
=========== =========== =========== ===========

Weighted average
common shares -
diluted 28,456 28,103 28,454 28,110
=========== =========== =========== ===========










Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets

(in thousands)


September 30, December 31,
2011 2010
-------------- --------------
(UNAUDITED)
Current assets:
Cash and cash equivalents $ 671,028 $ 906,551
Restricted cash - 6,422
Short-term investments 239,174 118,636
Accounts receivable, net 375,031 387,996
Inventories, net 445,581 398,100
Other current assets 146,889 157,641
-------------- --------------
Total current assets 1,877,703 1,975,346

Property, plant and equipment, net 338,942 333,617
Goodwill, net 371,227 363,981
Purchased intangibles, net 180,228 203,881
Other assets 201,695 185,939
-------------- --------------
Total assets $ 2,969,795 $ 3,062,764
============== ==============


Current liabilities:
Accounts payable $ 113,476 $ 113,440
Accrued payroll and employee benefits 120,167 131,381
Notes payable and current maturities of
long-term debt 806 233,181
Income and other taxes payable 46,368 50,935
Other current liabilities 134,509 137,690
-------------- --------------
Total current liabilities 415,326 666,627

Long-term debt, net of current maturities 731,597 731,100
Other long-term liabilities 129,226 124,518
-------------- --------------
Total liabilities 1,276,149 1,522,245

Bio-Rad stockholders' equity 1,693,149 1,536,696
Noncontrolling interests 497 3,823
-------------- --------------
Total stockholders' equity 1,693,646 1,540,519
-------------- --------------
Total liabilities and stockholders' equity $ 2,969,795 $ 3,062,764
============== ==============










Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows

(in thousands)
(UNAUDITED)


Nine Months
Ended September 30,

2011 2010
------------- -------------

Cash flows from operating activities:
Cash received from customers $ 1,508,934 $ 1,367,777
Cash paid to suppliers and employees (1,249,674) (1,143,699)
Interest paid (46,086) (48,812)
Income tax payments (38,029) (50,254)
Other operating activities 6,094 509
------------- -------------
Net cash provided by operating activities 181,239 125,521

Cash flows from investing activities:
Payments for acquisitions and long-term
investments (8,698) (88,694)
Other investing activities (205,191) (75,716)
------------- -------------
Net cash used in investing activities (213,889) (164,410)

Cash flows from financing activities:
Long-term borrowings - 2,000
Payments on long-term borrowings (226,615) (5,441)
Other financing activities 14,788 10,664
------------- -------------
Net cash (used in) provided by financing
activities (211,827) 7,223

Effect of foreign exchange rate changes on
cash 8,954 12,368
------------- -------------

Net decrease in cash and cash equivalents (235,523) (19,298)
Cash and cash equivalents at beginning of
period 906,551 649,938
------------- -------------
Cash and cash equivalents at end of period $ 671,028 $ 630,640
============= =============


Reconciliation of net income including
noncontrolling interests to net cash provided
by operating activities:


Net income including noncontrolling interests $ 118,822 $ 118,998
Adjustments to reconcile net income including
noncontrolling interests to net cash provided
by operating activities:

Depreciation and amortization 88,127 79,964
Changes in working capital (49,450) (73,589)
Other 23,740 148
------------- -------------
Net cash provided by operating activities $ 181,239 $ 125,521
============= =============



For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000

http://ih.advfn.com/p.php?pid=nmona&article=49763989


👍️0
SAE SAE 13 years ago
TPG Cap Finally Acqu Immucor [Bio-Rad mentioned, specific to reagents, Stockinvestor]- Analyst Blog

Recently, IVD Acquisition Corporation, an affiliate of TPG Capital, successfully completed the acquisition of Immucor, Inc. (BLUD) for $27 per share or $1.9 billion in total.

The deal was announced initially in July.

Established in 1992 with $48 billion of assets under management, TPG Capital is a leading global private investment firm with offices spread across the globe.

Immucor, manufacturer and seller of automated systems and reagents, suffered several setbacks over the past few quarters on the back of a slowdown in the blood industry. Several small donor centers have closed their operations due to lackluster demand arising from the economic uncertainty. Tighter hospital budgets and uncertainty in the healthcare market also led to a decline in orders and delayed the decision making process. Moreover, a higher number of uninsured and underinsured patients negatively influenced the demand in this industry.

Revenues from traditional reagents (61% of sales) were negatively impacted in the recent past. Immucor lost some traditional reagent customers due to its inability to provide the required services and attention as it emphasized on instruments.

The company was also hampered by several quality control issues. Moreover, in June this year, Immucor’s President and CEO Dr. Gioacchino De Chirico resigned and was replaced by Joshua H. Levine (former President and CEO of Mentor Corporation). In addition, Immucor operates in a highly competitive market, which boasts major players like Ortho-Clinical Diagnostics of Johnson & Johnson (JNJ) and Bio-Rad Laboratories (BIO).

However, Immucor is expected to be an attractive investment as the US blood market is likely to improve in the upcoming years on the back of ageing population as these surgeries are typically associated with old age. TPG Capital, with improved strategic interference, is expected to turnaround its business and drive growth going forward.

http://ih.advfn.com/p.php?pid=nmona&article=48914897

👍️0
SAE SAE 13 years ago
Bio-Rad Receives FDA Premarket Application Approval for Its Fourth-Generation HIV Assay

Press Release Source: Bio-Rad Laboratories On Monday July 25, 2011, 8:30 am EDT

HERCULES, CA--(Marketwire - 07/25/11) - Bio-Rad Laboratories, Inc. (NYSE:BIO - News) and (NYSE:BIO.B - News), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme immunoassay).

The GS HIV Combo Ag/Ab EIA detects HIV antigens (proteins that are part of the HIV virus) and HIV antibodies (proteins that are produced by the body to fight the HIV infection), offering early detection of HIV infections, including acute HIV infections. Clinical studies were performed at five major institutions in the United States on a large sample population including adult and pediatric patients in high and low risk populations.

According to the most recent information published by the U.S. Centers for Disease Control, "more than one million people are living with HIV in the United States. One in five (21%) of those people living with HIV is unaware of their infection. An estimated 56,300 Americans become infected with HIV each year." Early detection of HIV leads to early treatment and helps prevent new infections of the virus.

"Bio-Rad is pleased to offer its fourth-generation HIV assay in the U.S.," said John Goetz, Bio-Rad Vice President and Group Manager of Clinical Diagnostics. "Detecting HIV antigens and HIV antibodies in the same test provides clinicians with the ability to detect the virus at an earlier stage. This results in faster diagnosis of HIV-infected individuals so they are able to get the treatment they need more quickly. Bio-Rad has a long history of providing laboratories the tools that they need for HIV detection. We will continue to remain in the forefront of this critical area."

About the GS HIV Combo Ag/Ab EIA Assay
The GS HIV Combo Ag/Ab EIA is an enzyme immunoassay kit for the simultaneous qualitative detection of Human Immunodeficiency Virus (HIV) p24 antigen and antibodies to HIV Type 1 (HIV-1 groups M and O) and HIV Type 2 (HIV-2) in human serum or plasma. The kit is intended to be used as an aid in the diagnosis of infection of HIV-1 and/or HIV-2 in adults and children as young as two years of age. The kit can run on Bio-Rad's EVOLIS™ system, a self-contained automated microplate processor, and the kits may also be used with manual testing systems.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE:BIO - News) and (NYSE:BIO.B - News), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Contact:
For more information, please contact:Bio-Rad Laboratories, Inc.Tina CucciaCorporate Communications510-724-7000
http://investorshub.advfn.com/boards/post_new.aspx?board_id=12125
👍️0
SAE SAE 13 years ago
Bio-Rad to Report Second-Quarter 2011 Financial Results Tuesday, August 2, 2011

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the second quarter 2011 on Tuesday, August 2, 2011, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

Interested parties may access the call by dialing 866-277-1181 (in the U.S.) or 617-597-5358 (international), access number 35139244.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 87791245, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, please visit www.bio-rad.com.

For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000

http://ih.advfn.com/p.php?pid=nmona&article=48416154
👍️0
SAE SAE 13 years ago
Bio-Rad Launches Antiphospholipid Syndrome IgG, IgM, and IgA Kits for Its BioPlex 2200 System

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the European and Canadian launch of its BioPlex® 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits for use on its BioPlex® 2200 system. Antiphospholipid Syndrome is an autoimmune disease in which the body's immune system mistakenly produces antibodies to certain blood proteins causing thrombosis (clotting) within arteries, veins, and small blood vessels.

Patients with Antiphospholipid Syndrome are at risk of strokes and heart attacks. In addition, thrombosis within arteries and veins has the potential to affect other organs such as the lungs, liver, and kidney.

The BioPlex 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits are used as an aid in the diagnosis of this disease by simultaneously detecting two autoantibodies (anti-Cardiolipin and anti-Beta-2 Glycoprotein I) and therefore leading to faster and better care for those suffering from this syndrome.

"The release of the Antiphospholipid Syndrome reflects our continued commitment to expand our menu around the BioPlex 2200 testing system," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "By obtaining multiplex results from a single patient sample, laboratories and physicians can get the answers they need to provide faster and more effective patient treatment."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests, which are traditionally processed separately, using a single small volume patient sample.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia

Corporate Communications

510-724-7000


http://ih.advfn.com/p.php?pid=nmona&article=47712260
👍️0
SAE SAE 13 years ago
Bio-Rad Reports First-Quarter Currency-Neutral Revenue Growth of 4.9 Percent

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2011.

First-quarter reported revenues were $485.1 million, up 6.8% compared to $454.2 million reported for the first quarter of 2010. On a currency-neutral basis, quarterly revenues increased 4.9% compared to the same period last year. First-quarter gross margin was 57.2% compared to 56.6% during the same quarter last year. Net income attributable to Bio-Rad for the first quarter of 2011 was $33.0 million, or $1.16 per share on a fully diluted basis compared to $1.24 per share, during the same period last year. Earnings per share in the first quarter was negatively impacted by one-time expenses of approximately $4 million related to the retirement of debt as well as a higher effective tax rate for the quarter, primarily due to adjustments to foreign tax credits.

"Performance in the first quarter reflects strength across many of our product areas," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "As we had anticipated, budgetary constraints faced by some of our customers outside the U.S. had an impact on our performance during the quarter. As the year progresses, we will continue to seek opportunities to improve our operational efficiencies and grow our business."

Life Science

The Life Science segment net sales for the first quarter were $154.5 million, up 2.1% compared to the first quarter of 2010. On a currency-neutral basis, Life Science segment sales were essentially flat compared to the same period last year. Sales in the U.S. for the Life Science segment were strong but were offset by a continued slowness during the first quarter in markets outside the U.S., primarily in Europe and Japan. Sales of recently introduced products continued to gain rapid customer acceptance in the first quarter, these include the TC10™ automated cell counter as well as the Mini-PROTEAN® TGX™ precast electrophoresis gel product line. In March, Bio-Rad launched the Trans-Blot® Turbo™ transfer system, a rapid western blotting instrument that allows researchers to efficiently transfer proteins from gel to blot in three minutes.

Clinical Diagnostics

The Clinical Diagnostics segment reported net sales of $327.2 million for the first quarter, up 9.1% compared to the first quarter in 2010. On a currency-neutral basis, net sales were up 7.3% from the same period last year. These gains were largely due to growth across product lines most notably blood typing, quality controls, and microbiology. Performance in the Clinical Diagnostics segment also benefited from placements of the Company's BioPlex® 2200 system in addition to sales of assays that run on the system. Customer interest of the Company's IH-1000 blood typing system continues to increase in markets outside the U.S. The instrument is a fully-automated, high-throughput system designed for the blood transfusion laboratory.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) May 3, 2011. Interested parties may access the call by dialing 800-261-3417 (in the U.S.) or 617-614-3673 (international), access number 12268652.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 45024697, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.


Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Income

(in thousands, except per share data)
(UNAUDITED)

Three Months Ended
March 31,
--------------------------
2011 2010
------------ ------------
Net sales $ 485,121 $ 454,234
Cost of goods sold 207,510 197,107
------------ ------------
Gross profit 277,611 257,127

Selling, general and administrative expense 167,763 153,617
Research and development expense 42,730 40,263
------------ ------------
Income from operations 67,118 63,247

Interest expense 16,766 14,444
Foreign exchange losses (gains), net 3,042 (217)
Other (income) expense, net (951) (799)
------------ ------------
Income before income taxes 48,261 49,819

Provision for income taxes (15,323) (14,427)
------------ ------------
Net income including noncontrolling interests 32,938 35,392

Net loss (income) attributable to
noncontrolling interests 101 (531)
------------ ------------
Net income attributable to Bio-Rad $ 33,039 $ 34,861
============ ============

Basic earnings per share:
Net income per share basic attributable to
Bio-Rad $ 1.18 $ 1.27
============ ============

Weighted average common shares - basic 27,904 27,545
============ ============

Diluted earnings per share:
Net income per share diluted attributable to
Bio-Rad $ 1.16 $ 1.24
============ ============

Weighted average common shares - diluted 28,389 28,072
============ ============




Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets

(In thousands)
(UNAUDITED)

March 31, December 31,
2011 2010
------------- -------------
Current assets:
Cash and cash equivalents $ 627,908 $ 906,551
Restricted cash 6,533 6,422
Short-term investments 163,528 118,636
Accounts receivable, net 388,554 387,996
Inventories 429,975 398,100
Other current assets 180,812 157,641
------------- -------------
Total current assets 1,797,310 1,975,346

Property, plant and equipment, net 337,625 333,617
Goodwill, net 369,107 363,981
Purchased intangibles, net 198,658 203,881
Other assets 206,073 185,939
------------- -------------
Total assets $ 2,908,773 $ 3,062,764
============= =============



Current liabilities:
Accounts payable $ 111,373 $ 113,440
Accrued payroll and employee benefits 116,733 131,381
Notes payable and current maturities of
long-term debt 10,269 233,181
Income and other taxes payable 59,658 50,935
Other current liabilities 129,558 137,690
------------- -------------
Total current liabilities 427,591 666,627

Long-term debt, net of current maturities 731,214 731,100
Other long-term liabilities 136,480 124,518
------------- -------------
Total liabilities 1,295,285 1,522,245

Bio-Rad stockholders' equity 1,612,292 1,536,696
Noncontrolling interests 1,196 3,823
------------- -------------
Total stockholders' equity 1,613,488 1,540,519
------------- -------------
Total liabilities and stockholders'
equity $ 2,908,773 $ 3,062,764
============= =============




Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows

(In thousands)
(UNAUDITED)

Three Months Ended
March 31,
2011 2010
------------ ------------
Cash flows from operating activities:
Cash received from customers $ 496,749 $ 445,669
Cash paid to suppliers and employees (436,430) (389,505)
Interest paid (22,189) (21,086)
Income tax payments (18,373) (13,279)
Other operating activities 25 470
------------ ------------
Net cash provided by operating activities 19,782 22,269


Cash flows from investing activities:
Payment for acquisitions and long-term
investments (3,571) (66,496)
Other investing activities (73,722) (10,518)
------------ ------------
Net cash used in investing activities (77,293) (77,014)

Cash flows from financing activities:
Payments on long-term borrowings (225,763) (1,595)
Other financing activities 11,020 2,628
------------ ------------
Net cash (used in) provided by financing
activities (214,743) 1,033

Effect of foreign exchange rate changes on cash (6,389) 1,908
------------ ------------

Net decrease in cash and cash equivalents (278,643) (51,804)
Cash and cash equivalents at beginning of
period 906,551 649,938
------------ ------------
Cash and cash equivalents at end of period $ 627,908 $ 598,134
============ ============


Reconciliation of net income including
noncontrolling interests to net cash
provided by operating activities:

Net income including noncontrolling interests $ 32,938 $ 35,392
Adjustments to reconcile net income including
noncontrolling interests to net cash provided
by operating activities:
Depreciation and amortization 28,115 27,548
Changes in working capital (54,625) (32,746)
Other 13,354 (7,925)
------------ ------------
Net cash provided by operating activities $ 19,782 $ 22,269
============ ============


For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000

http://ih.advfn.com/p.php?pid=nmona&article=47514306
👍️0
SAE SAE 13 years ago
Bio-Rad to Report First-Quarter 2011 Financial Results Tuesday, May 3, 2011

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the first quarter 2011 on Tuesday, May 3, 2011, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Interested parties may access the call by dialing 800-261-3417 (in the U.S.) or 617-614-3673 (international), access number 12268652.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 45024697, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, please visit www.bio-rad.com.

For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000

Email Contact


👍️0
SAE SAE 13 years ago
Bio-Rad Reports Record Fourth-Quarter and Full-Year 2010 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2010.

Fourth-quarter reported revenues were $533.7 million, up 7.8% compared to $495.1 million reported for the fourth quarter of 2009. On a currency-neutral basis, quarterly revenues increased 9.9% compared to the same period last year. This increase was the result of organic growth across Bio-Rad's two main areas, Life Science and Clinical Diagnostics as well as revenue of $15.3 million resulting from the acquisition of certain diagnostics businesses of Biotest AG, which were added to the Company's portfolio in the first quarter of 2010. Excluding the revenue from the Biotest acquisition, fourth-quarter revenues were up 6.7% on a currency neutral basis. Fourth-quarter gross margin increased to 56.2% compared to 54.2% during the same quarter last year.

Net income attributable to Bio-Rad for the fourth quarter of 2010 was $67.9 million, or $2.41 per share on a fully diluted basis compared to $1.35 per share, during the same period last year. In December, the Company refinanced a portion of its long-term debt issuing $425 million of senior debt. Proceeds were used to retire $200 million of subordinated debt in December and, subsequent to year end, $225 million of subordinated debt. The effect of this transaction on pretax earnings for the fourth quarter of 2010 was $5.3 million, which is included in interest expense.

The tax provision for the fourth quarter was a benefit of $10.7 million. This extraordinary fourth-quarter provision benefit includes the repatriation of foreign earnings to the U.S. and the favorable impact of the extension of the U.S. Research and Experimentation tax credit. Without these two items, the fourth-quarter effective tax rate would have been approximately 25%.

For the full year, sales grew by 8.0% to $1,927.1 million compared to $1,784.2 million in 2009. Year over year, there was insignificant currency impact on sales growth. Full-year net income attributable to Bio-Rad was $185.5 million, or $6.59 per share on a fully diluted basis, compared to $144.6 million, or $5.20 per share, respectively, in 2009. Full-year gross margin increased to 56.6% compared to last year's figure of 56.0%.

"We are pleased by our performance during the fourth quarter and the entire year," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "In spite of a cautious business environment in the U.S. and Europe throughout 2010, we are encouraged by customer acceptance of several new products including our TC10™ automated cell counter and our IH-1000 automated blood typing platform. Although continued economic pressure from European markets is predicted, we expect 2011 to be another year of progress for Bio-Rad."

Life Science

The Life Science segment net sales for the fourth quarter were $192.9 million, up 1.0% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 2.2%. Full-year reported revenues for the Life Science segment were $648.1 million, up 2.6% over the prior year, or an increase of 2.2% on a currency-neutral basis. European sales continued to lag in the fourth quarter as a result of weak economic conditions facing government-funded research. During the quarter, the Life Science segment benefited from sales of precast electrophoresis gels as well as its next generation PCR instruments, in particular, the CFX96™ real-time PCR detection system.

The TC10 automated cell counter also continued to gain rapid customer acceptance on a global basis. In November, Bio-Rad launched the Criterion® TGX Stain-Free™ precast electrophoresis gels which, when combined with Bio-Rad's Gel Doc™ EZ imager, provide researchers with the fastest protein separation and visualization available.

Clinical Diagnostics

The Clinical Diagnostics segment reported net sales of $336.5 million for the fourth quarter, up 12.0% compared to the same period in 2009. On a currency-neutral basis, net sales were up 14.7%. These results include additional revenue of $15.3 million from the diagnostics businesses of Biotest AG that were added to the Company's portfolio in the first quarter of 2010. Excluding revenue from the Biotest acquisition, net sales were up 9.3% on a currency-neutral basis compared to the same quarter last year. Full-year reported revenues for the Clinical Diagnostics segment were $1,265.3 million, an increase of 11.0% over the prior year. On a currency-neutral basis, full-year sales increased 11.3% compared to 2009 results. Excluding revenue from the Biotest acquisition, full-year sales increased 6.3% on a currency neutral basis. Performance in the Clinical Diagnostics segment during the fourth quarter was the result of growth across all product lines, most notably quality controls, blood typing, diabetes monitoring, as well as sales of the BioPlex 2200® system. During the fourth quarter, the Company announced FDA clearance and the U.S. launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis. This novel marker has been shown to have superior diagnostic specificity.

2010 Full-Year Highlights


-- Full-year Company sales grew by 8.0% to $1,927.1 million.
-- Year-over-year net income was $185.5 million, or $6.59 per share on a
fully diluted basis, compared to $144.6 million, or $5.20 per share in
2009.
-- In January, Bio-Rad completed the purchase of certain diagnostics
businesses of Biotest AG including its diagnostics products in the
areas of blood transfusion testing, transplantation, and infectious
diseases.
-- Also, in January, Bio-Rad announced the launch of a new Anti-CCP test
for markets outside the U.S. for its BioPlex 2200 system for the early
detection of rheumatoid arthritis. After receiving FDA clearance later
in the year, the product was launched in the U.S.
-- In March, Bio-Rad announced the launch of the Mini-PROTEAN® TGX™
precast gels that provide researchers with the fastest running, long
shelf life precast gels for protein electrophoresis.
-- In May, Bio-Rad introduced the TC10 automated cell counter, which
accurately and reproducibly provides total mammalian cell counts in 30
seconds, eliminating the need for manually counting cells.
-- Also in May, the Clinical Diagnostics segment announced the launch of
the BioPlex® 2200 MMRV IgG kit (measles, mumps, rubella, and the
varicella-zoster virus) for use on the company's BioPlex 2200 system.
-- During the second quarter, Bio-Rad received notification from the FDA
that it could proceed with an Investigational New Drug Study for its
Dengue NS1 Ag microplate assay.
-- In June, Bio-Rad announced the launch of its IH-1000 blood screening
system for markets outside the U.S.
-- In July, Bio-Rad submitted Premarket Approval application to the FDA
for its fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme
immunoassay), offering early detection of HIV infections as well as
acute HIV infections.
-- In September, Bio-Rad announced the launch of the Gel Doc EZ imager,
the first gel documentation system that provides publication-quality
images and analysis in seconds.
-- In November, the Life Science segment launched Criterion TGX Stain-Free
precast gels which, when combined with Bio-Rad's Gel Doc EZ imager,
provide researchers with the fastest protein separation and
visualization available.
-- In December, Bio-Rad successfully issued $425 million of senior debt.
As a result of that transaction, the Company redeemed $200 million of
subordinated debt originally due in 2014. Subsequently, in January
2011, the Company redeemed $225 million of subordinated debt originally
due 2013...Much more at link below, Stockinvestor


http://ih.advfn.com/p.php?pid=nmona&article=46616267
👍️0
SAE SAE 13 years ago
Bio-Rad to Report Fourth-Quarter and Full-Year 2010 Financial Results Thursday, February 24, 2011


Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2010 on Thursday, February 24, 2011, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

Interested parties may access the call by dialing 866-202-0886 (in the U.S.) or 617-213-8841 (international), access number 25027707.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 51107717, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit www.bio-rad.com.

For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000


👍️0
SAE SAE 13 years ago
Bio-Rad Announces Public Offering of $425 Million Senior Notes
Today : Monday 6 December 2010

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it intends to commence an offering, subject to market and other conditions, of $425 million aggregate principal amount of senior notes due 2020 (the "Senior Notes") in a public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. The interest rate and other terms of the Senior Notes are to be determined by negotiations between the Company and the underwriters of the Senior Notes. The Company intends to use the proceeds from this offering, together with cash on hand, to redeem all $225 million of its outstanding 7.50% senior subordinated notes due 2013 and all $200 million of its outstanding 6.125% senior subordinated notes due 2014.

Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering of the Senior Notes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Senior Notes or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus and the related prospectus supplement. Copies of the prospectus and related prospectus supplement regarding the offering of the Senior Notes may be obtained from Bio-Rad Laboratories, Inc. at 1000 Alfred Nobel Drive, Hercules, California, 94547 or from Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements about the offering of the Senior Notes and our intent to redeem certain of our outstanding senior subordinated notes and are based on our current expectations. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer, or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

Phone: 510-724-7000

http://ih.advfn.com/p.php?pid=nmona&article=45530348

👍️0
SAE SAE 13 years ago
Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of More Than 5 Percent
Today : Wednesday 3 November 2010

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2010.

Third-quarter reported revenues were $471.5 million, up 2.3% compared to $461.1 million reported for the third quarter of 2009. On a currency-neutral basis, quarterly revenues increased 5.4% compared to the same period last year. Reflected in these results is $13.6 million additional revenue generated by certain diagnostics businesses of Biotest AG, which were added to the Company's portfolio in the first quarter of 2010. Excluding the revenue from the Biotest acquisition, third-quarter revenues were down 0.7% or up 2.2% on a currency neutral basis, compared to the same period last year. Third-quarter gross margin was 56.5%, unchanged, compared to the same quarter in 2009.

Net income attributable to Bio-Rad for the third quarter was $44.8 million or $1.59 per share on a fully diluted basis versus $1.38 per share reported for the same period last year.

Year-to-date revenues grew by 8.1% to $1.4 billion compared to the first three quarters in 2009. Adjusting for the impact of currency, revenue growth was 7.3%. Excluding the additional revenue from the Biotest acquisition, year-to-date organic revenues grew by 4.9%, or 4.1% on a currency-neutral basis.

Year-to-date net income attributable to Bio-Rad for 2010 was $117.6 million, or $4.18 per share on a fully diluted basis, compared to $106.8 million, or $3.85 per share, respectively, during the same period in 2009.

"Third-quarter results show consistency in many of our core product areas in spite of some weak markets in the U.S. and abroad," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "As the year wraps up, we will carefully monitor economic pressure on our global operation and look for new opportunities to grow our business."

Life Science

The Life Science segment net sales for the third quarter were $153.2 million, up 1.9% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 3.5% compared to the third quarter of 2009. Sales growth of the Life Science segment in the U.S. reflects strength in spending by academic and biopharmaceutical customers; European sales continue to lag due to weak economic conditions facing government-funded research. Performance of the segment benefited from strong sales of core product lines including the Company's next generation PCR instruments, in particular, the CFX96™ real-time PCR detection system and associated reagents as well as the TC10™ automated cell counter, which was introduced earlier this year. Bio-Rad's Mini-PROTEAN® TGX™ precast electrophoresis gel product line, which offers high resolution and fast time to results is also continuing to gain customer acceptance.

Clinical Diagnostics

Reported net sales for the Clinical Diagnostics segment in the third quarter rose to $314.9 million, up 2.4% compared to the same quarter last year. On a currency-neutral basis, net sales were up 6.3%. These results reflect additional revenue of $13.6 million from the diagnostics businesses of Biotest AG that were added to the Company's portfolio in the first quarter. Excluding revenue from the Biotest acquisition, net sales were up 1.5 % on a currency-neutral basis compared to the same period last year. Overall performance of the Clinical Diagnostics segment was negatively affected by economic challenges impacting healthcare markets in the U.S. and Europe as well as certain sales in 2009 that did not recur in 2010. In July, Bio-Rad submitted a Premarket Approval application to the U.S. Food and Drug Administration for its fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme immunoassay). The test detects HIV antigens (proteins that are part of the HIV virus) and HIV antibodies (proteins that are produced by the body to fight the HIV infection), offering earlier detection of HIV infections.

Internal Control Over Financial Reporting

In connection with our audit committee's ongoing investigation of our compliance with the FCPA and internal control assessment by management and our internal audit group during our fiscal quarter ended September 30, 2010, we identified three significant deficiencies in our internal control over financial reporting as of September 30, 2010 that, when considered and taken together, constitute a material weakness in our internal control over financial reporting as of September 30, 2010. Our conclusion that we have a material weakness in our internal control over financial reporting as of September 30, 2010 is not based on quantified misstatements in our historical financial statements or our financial statements as of and for our fiscal quarter ended September 30, 2010, but instead on the risk that we may be unable to prevent or detect on a timely basis potential material errors in our future financial statements. We do not presently anticipate that the material weakness in our internal control over financial reporting as of September 30, 2010 will have any material effect on our previously reported financial results or our financial results for our fiscal quarter ended September 30, 2010. Our Quarterly Report on Form 10-Q for our fiscal quarter ended September 30, 2010 will contain more information about these three significant deficiencies and the resulting material weakness and the measures that we are considering initiating to attempt to remediate it.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 2, 2010. Interested parties may access the call by dialing 800-659-2032 (in the U.S.) or 617-614-2712 (international), access number 52899247.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 98042813, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements...

http://ih.advfn.com/p.php?pid=nmona&article=45045018

👍️0
SAE SAE 14 years ago
Bio-Rad and Axis-Shield Announce FDA Clearance and U.S. Launch of an Anti-CCP Test for Rheumatoid Arthritis for Bio-Rad's BioPle

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc (LSE: ASD) (OSE: ASD), an international and innovative in vitro diagnostics (IVD) company, today announced the U.S. Food and Drug Administration (FDA) clearance and U.S. launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis. The assay, which runs on Bio-Rad's BioPlex® 2200 system, measures anti-CCP (anti-cyclic citrullinated peptide antibodies), a novel marker that has been shown to have superior specificity in the diagnosis of rheumatoid arthritis. The BioPlex 2200 Anti-CCP assay is based on Axis-Shield's proprietary anti-CCP technology and was launched in territories outside the U.S. earlier in 2010.

"We are pleased to receive FDA clearance of our BioPlex 2200 anti-CCP assay as it allows us to expand our presence in the U.S. by offering a more compelling menu for infectious disease serology and autoimmune testing laboratories," said John Goetz, Bio-Rad Vice President and Group Manager of Clinical Diagnostics. "We believe the recent recommendation by the American College of Rheumatology and the European League Against Rheumatism to include anti-CCP in the definitive diagnosis of rheumatoid arthritis will further establish the growth of this important marker in autoimmune diagnostics."

"FDA market clearance for the anti-CCP test on Bio-Rad's novel BioPlex 2200 system represents an important milestone in the commercialization of the anti-CCP marker for rheumatoid arthritis," said Ian Gilham, Axis-Shield's Chief Executive Officer. "Test availability on this versatile analyzer represents the first time that anti-CCP has been offered on a multiplex autoimmune platform, and we believe this will encourage market expansion as the autoimmune nature of many conditions becomes increasingly recognized."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, consolidates workstations, and simplifies workflow.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit www.bio-rad.com.

About Axis-Shield

Axis-Shield is an international and innovative in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specializes in the supply of instruments and tests for the rapidly growing physician's office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, and diabetes. For more information on Axis-Shield, please refer to www.axis-shield.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia, Corporate Communications

510-724-7000

Email Contact



Axis-Shield plc

Ian Gilham, Chief Executive Officer

Ronny Hermansen, Financial Director

+44 (0) 203 178 7849



M:Communications

Mary-Jane Elliott / Emma Thompson

Tel:+44 207 920 2330
http://ih.advfn.com/p.php?pid=nmona&article=44767470&symbol=NY%5EBIO
👍️0
SAE SAE 14 years ago
Form 10-Q for BIO RAD LABORATORIES INC


--------------------------------------------------------------------------------

6-Aug-2010

Quarterly Report



Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
This discussion should be read in conjunction with the information contained in both our Consolidated Financial Statements for the year ended December 31, 2009 and this report for the three and six months ended June 30, 2010.

Other than statements of historical fact, statements made in this report include forward looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including among other things:
changes in general domestic and worldwide economic conditions; our ability to successfully develop and market new products; our reliance on and access to necessary intellectual property; our ability to successfully integrate any acquired business; our substantial leverage and ability to service our debt; competition in and government regulation of the industries in which we operate; and the monetary policies of various countries. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events, or otherwise except as required by Federal Securities law.

Overview. We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two primary segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics. We sell more than 8,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. Because our customers require standardization for their experiments and test results, much of our revenues are recurring. Approximately 32% of our year-to-date 2010 consolidated net sales are from the United States and approximately 68% are from international locations. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers and from lower international operating expenses.
The market for reagents and apparatus remains good while growth rates have slowed due to both public and private grant funding being more measured. The market for large capital equipment has slowed, as many pharmaceutical and biotechnology customers delayed or reduced their capital spending. We are generally less impacted by trends in capital spending as lower priced reagents and apparatus comprise more than 70% of product sales.

On January 6, 2010, we acquired certain diagnostic businesses of Biotest AG (Biotest). This 45 million Euro acquisition is expected to broaden our product offering in the area of immunohematology and provide access to the U.S. markets for these products.

The following shows gross profit and expense items as a percentage of net sales:


Three Months Ended Six Months Ended
June 30, June 30,
2010 2009 2010 2009

Net sales 100.0 % 100.0 % 100.0 % 100.0 %
Cost of goods sold 42.6 43.4 43.0 43.1
Gross profit 57.4 56.6 57.0 56.9
Selling, general and administrative expense 33.4 33.6 33.6 34.3
Research and development expense 9.4 9.9 9.1 9.6
Net income attributable to Bio-Rad 8.1 8.9 7.9 8.2




Critical Accounting Policies and Estimates

As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2009, we have identified accounting for income taxes, valuation of goodwill and long-lived assets, valuation of inventories, warranty reserves, valuation of investments, allowance for doubtful accounts and litigation accruals as the accounting policies and estimates critical to the operations of Bio-Rad.

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the six months ended June 30, 2010 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009. For a full discussion of these policies, please refer to our Form 10-K for the period ended December 31, 2009.


Three Months Ended June 30, 2010 Compared to

Three Months Ended June 30, 2009
Corporate Results -- Sales, Margins and Expenses

Net sales (sales) in the second quarter of 2010 increased 9.5% to $467.7 million from $427.2 million in the second quarter of 2009, with Biotest contributing approximately $14.5 million to the growth in sales. Excluding the impact of foreign currency, second quarter 2010 sales increased by approximately 9.0% compared to the same period in 2009. Currency neutral sales growth, excluding Biotest, was reflected in all regions, but primarily for Asia Pacific and Emerging Markets.

The Life Science segment sales for the second quarter of 2010 was relatively flat with sales of $150.7 million compared to $149.7 million in the same period last year. On a currency neutral basis, there was a slight decrease in sales for the second quarter of 2010 compared to the second quarter of 2009. We have seen weakness in government support and spending for research and development, especially in Europe.

The Clinical Diagnostics segment reported sales for the second quarter of 2010 of $314.1 million, an increase of 14.5% compared to the same period last year, with Biotest contributing approximately 5.3% to the sales growth. On a currency neutral basis, sales increased 14.1% including Biotest compared to the second quarter of 2009. Clinical Diagnostics product lines showing growth were immunohematology (before the contribution of Biotest), quality controls and reagent products. The most significant sales growth was in the Asia Pacific and Emerging Markets regions.

Consolidated gross margins were 57.4% for the second quarter of 2010 compared to 56.6% for the second quarter of 2009. Life Science segment gross margins for the second quarter of 2010 improved from the same period last year by approximately 1.6%. The increase was primarily due to improved manufacturing overhead absorption and a reduction in costs. Clinical Diagnostics segment gross margins for the second quarter of 2010 were relatively flat compared to the same period last year. Biotest had a negative impact on Clinical Diagnostics gross margins primarily due to overall generally lower margins than historical segment gross margins as a result of purchase accounting, lower volumes related to total capacity and a current higher cost structure.
Increases in Clinical Diagnostics gross margins were from the settlement of intellectual property disputes.

Selling, general and administrative expenses (SG&A) represented 33.4% of sales for the second quarter of 2010 compared to 33.6% of sales for the second quarter of 2009. Growth in absolute SG&A spending was less than sales growth.
Increases were primarily driven by employee related costs, marketing, travel, and professional services.

Research and development expense increased to $43.9 million in the second quarter of 2010 compared to $42.4 million in the second quarter of 2009. Life Science segment research and development expense increased from the prior year quarter. Life Science segment efforts concentrated on genomics, proteomics and process chromatography applications. Clinical Diagnostics segment research and development expense was flat compared to the prior year period as the prior year had larger spending for the recently released IH 1000 blood typing system and the spending increased during the second quarter of 2010 for other projects.

Corporate Results - Other Items

Interest expense for the second quarter of 2010 increased by $4.0 million compared to the second quarter of 2009. An additional $300 million of 8.0% Senior Subordinated Notes due in 2016 were issued in May 2009, which increased our interest expense compared to the second quarter of 2009. Our other principal debt obligations are the 2003 and 2004 Senior Subordinated Notes totaling $425.0 million, which carry fixed rates of interest of 7.5% and 6.125%, respectively.

Foreign currency exchange gains and losses consist of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Foreign currency exchange losses, net for the quarter ended June 30, 2010 and 2009 were primarily attributable to market volatility, costs to hedge, and the result of the estimating process inherent in the timing of shipments and payments of intercompany debt.

Other income, net for the second quarter of 2010 was $2.5 million compared to $6.3 million for the second quarter of 2009, a decrease of $3.8 million. The decrease primarily resulted from non-recurring income of $4.6 million in 2009 related to the relief of a foreign non-income based tax obligation.

Our effective tax rate was 30% and 20% for the second quarter of 2010 and 2009, respectively. The effective tax rates for the second quarter of 2010 and 2009 both reflected tax benefits for nontaxable dividend income, research and development tax credits, and differences between U.S. and foreign rates. The higher effective tax rate for the second quarter of 2010 was primarily due to a decline in the percentage of total earnings earned in lower tax jurisdictions, the expiration of the research and development tax credit in the U.S. and an increase in the liability for uncertain tax positions.

Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including but not limited to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.


Six Months Ended June 30, 2010 Compared to

Six Months Ended June 30, 2009
Corporate Results - Sales, Margins and Expenses

Net sales (sales) in the first half of 2010 increased 11.3% to $921.9 million from $828.1 million in the first half of 2009, with Biotest contributing approximately $27.2 million to the growth in sales. Excluding the impact of foreign currency, second quarter 2010 sales increased by approximately 8.4% compared to the same period in 2009. Currency neutral sales growth, excluding Biotest, was achieved in all regions, but primarily in Asia Pacific and Emerging Markets.

The Life Science segment sales for the first half of 2010 were $302.0 million, an increase of 4.1%, or 1.6% on a currency neutral basis, compared to the same period last year. Sales growth was primarily attributed to real-time PCR products, offset by general market weakness, especially in Europe. Currency neutral sales growth in the Life Science segment was primarily in Asia Pacific and North America, while European sales declined.

The Clinical Diagnostics segment reported sales for the first half of 2010 of $613.9 million, an increase of 15.4% compared to the same period last year, with Biotest contributing approximately 5.1% to the sales growth. On a currency neutral basis, sales increased 12.3% including Biotest compared to the first half of 2009. Clinical Diagnostics product lines generating growth were immunohematology (before the contribution of Biotest), quality controls and reagent products. Sales growth was primarily in Asia Pacific.

Consolidated gross margins were 57.0% for the first half of 2010 compared to 56.9% for the first half of 2009. Life Science segment gross margins for the first half of 2010 improved from the same period last year by approximately 1.6%. The increase was primarily due to improved manufacturing overhead absorption and a reduction in costs. Clinical Diagnostics segment gross margins for the first half of 2010 decreased by approximately 0.7% from the same period last year. The Biotest acquisition had a negative impact on Clinical Diagnostics gross margins due to purchase accounting and overall generally lower margins than historical segment gross margins as a result of current lower volumes and a current higher cost structure. Offsetting this decrease in gross margins was the settlement of intellectual property disputes.

Selling, general and administrative expenses (SG&A) represented 33.6% of sales for the first half of 2010 compared to 34.3% of sales for the first half of 2009. Growth in absolute SG&A spending was less than sales growth. Increases were primarily driven by employee related costs, marketing, travel and professional services.

Research and development expense increased to $84.1 million in the first half of 2010 compared to $79.6 million in the first half of 2009. Life Science segment research and development expense increased from the prior year period. Life Science segment efforts concentrated on genomics, proteomics and process chromatography applications. Clinical Diagnostics segment research and development expense increased from the prior year period. The majority of the increase was related to immunohematology, with additional emphasis in clinical systems, clinical microbiology and blood virus diagnostic tests.

Corporate Results - Other Items

Interest expense for the first half of 2010 increased by $10.6 million compared to the first half of 2009. An additional $300 million of 8.0% Senior Subordinated Notes due in 2016 were issued in May 2009, which increased our interest expense compared to the prior year period. Our other principal debt obligations are the 2003 and 2004 Senior Subordinated Notes totaling $425.0 million, which carry fixed rates of interest of 7.5% and 6.125%, respectively.

Foreign currency exchange gains and losses consist of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Foreign currency exchange losses, net for the six months ended June 30, 2010 and 2009 were primarily attributable to market volatility, costs to hedge and the result of the estimating process inherent in the timing of shipments and payments of intercompany debt.

Other income, net for the first half of 2010 was $3.3 million compared to $5.1 million for the first half of 2009. The decrease primarily resulted from non-recurring income of $4.6 million in 2009 related to the relief of a foreign non-income based tax obligation, partially offset by $2.5 million of other-than-temporary impairment of investments.

Our effective tax rate was 30% and 23% for the first half of 2010 and 2009, respectively. The effective tax rates for the first half of 2010 and 2009 both reflected tax benefits for nontaxable dividend income, research and development tax credits, and differences between U.S. and foreign rates. The higher effective tax rate for the first half of 2010 was primarily due to a decline in the percentage of total earnings earned in lower tax jurisdictions, the expiration of the research and development tax credit in the U.S. and an increase in the liability for uncertain tax positions.

Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including but not limited to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade. Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world. Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.
Gross margins are generally sufficient to exceed normal operating costs. Funding for research and development of new products as well as routine outflows of capital expenditure and tax expense are covered by cash flow from operations. Our cash flow from operations is also sufficient to make interest payments. In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million Amended and Restated Credit Agreement (Credit Agreement) that was entered into in June 2010. Borrowings under the Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. We had no outstanding balance under the Credit Agreement as of June 30, 2010. The Credit Agreement expires on June 21, 2014.

At June 30, 2010, we had available $717.7 million in cash, cash equivalents and short-term investments. Under domestic and international lines of credit, we had $247.0 million available for borrowing as of June 30, 2010, of which $12.6 million is reserved for standby letters of credit issued by our banks to guarantee our obligations to various companies. Management believes that this availability together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and future acquisitions for the foreseeable future.

Cash Flows from Operations

Net cash provided by operations was $58.7 million and $111.9 million for the six months ended June 30, 2010 and 2009, respectively. The net decrease of $53.2 million primarily represents an increase in cash paid to suppliers including higher royalty payments and settlement payments of intellectual property disputes, higher payments on income taxes and higher interest payments from the $300 million bond offering in May 2009, partially offset by an increase in cash received from customers compared to the prior periods. Cash received from customers was at a slower rate than expected in 2010 due to a slowdown of cash collections in some European countries. We continue to focus on cash flow improvements as a global company-wide goal.

Cash Flows from Investing Activities

Net capital expenditures totaled $35.6 million and $33.4 million for the six months ended June 30, 2010 and 2009, respectively. Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansions, regulatory and environmental compliance, and leasehold improvements. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements. We anticipate accelerating expenditures in future periods to initiate expanding e-commerce platforms internationally and implementation of a global ERP system. These projects have not had the anticipated cash outflow as we have increased our due diligence in the selection of a system provider. All periods included reagent rental equipment placed with Clinical Diagnostics customers who then contract to purchase our reagents for use.

On January 6, 2010, we acquired certain diagnostic businesses of Biotest for 45 million Euros (approximately $64.9 million) in cash. This acquisition is included in our Clinical Diagnostics segment. We continue to review possible acquisitions to expand both our Life Science and Clinical Diagnostics segments.
We routinely meet with the principals or brokers of the subject companies. It is not certain that any of these transactions will advance beyond the preliminary stages to completion.

Cash Flows from Financing Activities

Net cash provided by financing activities was $4.2 million and $291.1 million for the six months ended June 30, 2010 and 2009, respectively. Cash provided in 2010 was primarily due to net proceeds from common stock, partially offset by repayments of long-term debt. Cash provided in 2009 was primarily due to the $300 million 8.0% Senior Subordinated Notes due in 2016 that was issued in May 2009. We have outstanding Senior Subordinated Notes due in 2013, 2014 and 2016 of $225.0 million, $200.0 million and $300.0 million, respectively.

http://biz.yahoo.com/e/100806/bio10-q.html
👍️0
SAE SAE 14 years ago
Bio-Rad Submits Premarket Approval Application to the FDA for Its Fourth-Generation HIV Assay [posting includes 2 announcements! GLTA, Stockinvestor]

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced that it has submitted a Premarket Approval application to the U.S. Food and Drug Administration for its fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme immunoassay).

The GS HIV Combo Ag/Ab EIA detects HIV antigens (proteins that are part of the HIV virus) and HIV antibodies (proteins that are produced by the body to fight the HIV infection), offering early detection of HIV infections as well as acute HIV infections. Clinical studies were performed at five major institutions in the United States on a large sample population including adult and pediatric patients with HIV infections, individuals in high and low risk groups, and pregnant women.

"The rate of acute HIV infections continues to increase in the United States and around the world," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "We look forward to being able to offer this assay in the U.S. as it is able to detect a significant number of additional cases of acute HIV infections compared to HIV antibody testing alone."

About GS HIV Combo Ag/Ab EIA Assay

The GS HIV Combo Ag/Ab EIA is an enzyme immunoassay used for the simultaneous qualitative detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma. The assay is intended to be used as an aid in the diagnosis of infection with HIV-1 and HIV-2.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,900 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information, contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia

Corporate Communications

510-724-7000

http://ih.advfn.com/p.php?pid=nmona&article=43739713&symbol=NY%5EBIO



Bio-Rad Introduces its IH 1000, an Automated Blood Screening System

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced the launch of its IH 1000 blood screening system.

The IH 1000 is a fully-automated, high-throughput system designed for the blood transfusion laboratory utilizing the industry accepted gold standard ID-System gel card technology. The new system offers full automation, integrated QC and validation, intuitive software, and walk-away convenience for blood banking laboratories.

"With the introduction of IH 1000, Bio-Rad offers a compelling new system designed specifically for the transfusion laboratory," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "Our customers who have already worked with the IH 1000 during our testing phase have said the system delivers the highest level of automation as well as improved workflow advantages -- without sacrificing the quality of the result." ...

http://ih.advfn.com/p.php?pid=nmona&article=43434928&symbol=NY%5EBIO
👍️0
SAE SAE 14 years ago
Bio-Rad Launches a Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG Kit for Its BioPlex 2200 System

HERCULES, CA -- (Marketwire)
05/24/10
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of the BioPlex® 2200 MMRV IgG kit for use on the company's BioPlex® 2200 system. The MMRV IgG kit (measles; mumps; rubella; and the varicella-zoster virus, which is commonly known as chicken pox) provides simultaneous results for the four tests that are commonly ordered together to determine a patient's susceptibility to MMRV.

The BioPlex 2200 MMRV IgG kit offers the advantage of multiplexing to deliver test results from a single patient sample. As a result, labs are able to generate test results quickly and with less effort. MMRV are infectious diseases that are preventable through vaccination. Maintaining high vaccination coverage and providing MMRV IgG results when an individual's status is uncertain is the most effective way to prevent disease outbreaks. Employees in healthcare facilities and military personnel, among others, are typically screened for MMRV IgG to ensure their safety.

"With the introduction of the BioPlex 2200 MMRV IgG kit, Bio-Rad offers a compelling menu for infectious disease serology and autoimmune testing laboratories," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "The MMRV IgG kit is the latest in our expanding menu of assays that run on our BioPlex 2200 system."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, consolidates workstations, and simplifies workflow.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.


For more information contact:

Tina Cuccia

Corporate Communications Manager

Bio-Rad Laboratories, Inc.

510-724-7000

Email Contact


http://ih.advfn.com/p.php?pid=nmona&article=42944804&symbol=NY%5EBIO

👍️0
SAE SAE 14 years ago
Bio-Rad Receives Notification From the FDA That It May Proceed With an Investigational New Drug Study for Its Dengue NS1 Ag Micr

HERCULES, CA and WASHINGTON, DC -- (Marketwire)
05/10/10
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and the American Red Cross, today announced that the U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research, has notified Bio-Rad that it may proceed with its Investigational New Drug (IND) study for the Bio-Rad Dengue NS1 Ag microplate assay. The Red Cross will use the immunoassay to screen approximately 80,000 blood donations from Puerto Rico, where dengue currently is endemic.

The Dengue NS1 Ag test is an easy-to-perform assay for detection of dengue NS1 antigen in serum or plasma. Bio-Rad introduced the Dengue NS1 Ag test in 2006 as the first and only available dengue antigen detection test on the market. The test is currently used in over 40 countries throughout the world. Results of the IND study may open the doors for Bio-Rad to introduce the Dengue NS1 Ag test to U.S. markets.

"Transfusion-transmitted dengue infections are a potential threat for blood recipients in Puerto Rico," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "Detection of the dengue NS1 antigen in patients' sera has proven to be a superior method for early diagnosis of a dengue infection."

About Dengue Fever

Dengue is an endemic disease affecting people in tropical and subtropical regions around the world and is considered the most important arboviral disease in terms of morbidity, mortality, and socio-economical costs. Dengue is transmitted by mosquitoes and no vaccine is currently available. The dengue NS1 antigen, detected by Bio-Rad's Dengue NS1 Ag microplate assay, identifies the presence of the dengue virus in the patient's blood. Since its introduction in 2006, numerous independent and international studies on the test have been published.

Dengue is currently endemic in more than 100 countries and has the potential to affect 40% of the earth's population. The World Health Organization estimates that there are about 50 to 100 million cases of dengue infections worldwide every year that result in 250,000 to 500,000 severely complicated forms of the disease and 24,000 deaths each year. The most affected regions are Southeast Asia, the Indian subcontinent, Latin America, and South America. Anyone travelling to these areas may contract the disease.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit www.bio-rad.com.

About the American Red Cross

The American Red Cross shelters, feeds, and provides emotional support to victims of disasters; supplies nearly half the nation's blood; teaches lifesaving skills; provides international humanitarian aid; and supports military members and their families. The Red Cross is a charitable organization -- not a government agency -- and depends on volunteers and the generosity of the American Public to perform its mission. For more information, please visit www.redcross.org or join our blog at http://blog.redcross.org.


For More information, contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia, Corporate Communications

510-724-7000

Email Contact

American Red Cross

Stephanie Millian, Biomedical Communications

202-303-4488

Email Contact

http://ih.advfn.com/p.php?pid=nmona&article=42735759&symbol=NY%5EBIO



👍️0
SAE SAE 14 years ago
Bio-Rad Reports First-Quarter 2010 Financial Results

HERCULES, CA -- (Marketwire)
05/04/10
Bio-Rad Laboratories, Inc. (NYSE: BIO) and

(NYSE: BIO.B), a multinational manufacturer and distributor of life science

research and clinical diagnostic products, announced financial results

today for the first quarter ended March 31, 2010.

First-quarter reported revenues were $454.2 million, up 13.3% compared to

$400.9 million reported for the first quarter of 2009. On a

currency-neutral basis, quarterly revenues increased 7.9% compared to the

same period last year. This increase was due to a combination of organic

growth across Bio-Rad's two main areas, Life Science and Clinical

Diagnostics, and the addition of certain diagnostics businesses of Biotest

AG to the Company's portfolio in the first quarter of 2010 that resulted in

additional revenue in the first quarter of $12.7 million. Excluding the

revenue from the Biotest acquisition, first-quarter revenues were up 10.1%

or 4.9% on a currency neutral basis, compared to the same period last year.

Net income attributable to Bio-Rad for the first quarter of 2010 was $34.9

million, or $1.24 per share on a fully diluted basis compared to $1.10 per

share, during the same period last year. First-quarter gross margin was

56.6% compared to 57.1% during the same quarter last year.

"Performance so far this year reflects strength across many of our product

areas," said Norman Schwartz, Bio-Rad President and Chief Executive

Officer. "During the first quarter we were pleased to add the new

diagnostics businesses to our operation. As the year continues, we will

focus on the seamless integration of these new products into our

organization and look for other opportunities to invest in our future."
Life Science

The Life Science segment net sales for the first quarter were $151.4

million, up 7.9% compared to the same period last year. On a

currency-neutral basis, Life Science segment sales increased by 3.4%. The

core Life Science product lines, excluding the impact from the BSE (bovine

spongiform encephalopathy) product line, grew at 9.7% compared to the same

period last year, or 5.3% on a currency-neutral basis. Performance in the

Life Science segment during the first quarter benefited from sales of the

ProteOn? protein interaction array system as well as the Company's next

generation PCR instruments, in particular, the CFX96? real-time thermal

cycler.

Bio-Rad's Mini-PROTEAN® TGX precast electrophoresis gel product line,

which launched in March, is gaining rapid customer acceptance by offering

ultra-fast time to results, high resolution, and extended shelf life. Also

in March, the Company introduced its TC10? automated cell counter, which

accurately provides total mammalian cell counts in 30 seconds or less,

providing a simple, rapid, and reproducible alternative to researchers who

manually count cells under the microscope using a hemocytometer.

Clinical Diagnostics

The Clinical Diagnostics segment reported net sales of $299.8 million for

the first quarter, up 16.4% compared to the prior-year quarter. On a

currency-neutral basis, net sales were up 10.5%. Excluding revenue from the

Biotest acquisition, net sales were up 11.5%, or 5.8% on a currency-neutral

basis, from the same period last year. These gains were largely due to

growth across all product line most notably quality controls, blood typing,

and diabetes monitoring. During the first quarter, Bio-Rad acquired

certain diagnostics businesses from Biotest AG, including its diagnostics

products in the areas of blood transfusion testing, transplantation, and

infectious diseases. Also during the quarter, Bio-Rad announced the launch

of an anti-CCP test for markets outside the U.S. The assay runs on

Bio-Rad's BioPlex® 2200 system and measures anti-CCP (anti-cyclic

citrullinated peptide antibodies), a novel marker that has been shown to

have superior specificity in the diagnosis of rheumatoid arthritis.

Management will discuss these results in a conference call at 2 PM Pacific

Time (5 PM Eastern Time) May 4, 2010. Interested parties may access the

call by dialing 800-599-9829 (in the U.S.) or 617-847-8703 (international),

access number 91876357.
A live webcast of the conference call may be accessed in the "Investor

Relations" section of www.bio-rad.com. A replay of the call will be

available at 888-286-8010 (in the U.S.) or 617-801-6888 (international),

access number 68368901, for seven days following the call. The webcast of

the call will be archived on the Bio-Rad site for on-demand replay for up

to a year and may be accessed in the "Investor Relations" section of

www.bio-rad.com.

Internal Investigation

The Company disclosed today that, based on an internal review by the

Company, the Company has identified conduct in certain of our overseas

operations that may have violated the anti-bribery provisions of the United

States Foreign Corrupt Practices Act ("FCPA"), the FCPA's books and records

and internal controls provisions, and the Company's own internal policies.
The Company has not assessed at this time whether any of the activities in

question violated the laws of the foreign jurisdictions in which they took

place. In May 2010, the Company voluntarily disclosed these matters to the

U.S. Department of Justice ("DOJ") and the Securities and Exchange

Commission ("SEC"). The Audit Committee of the Board of Directors has

assumed direct responsibility for reviewing these matters and has hired

experienced counsel to conduct an investigation and provide legal advice.

The Company intends to provide additional information to the DOJ and the

SEC as the Audit Committee's investigation progresses.

The Company is presently unable to predict the duration, scope, or result

of the Audit Committee's investigation, of any investigations by the DOJ or

the SEC or whether either agency will commence any legal action. The

outcome of any of the foregoing actions could have a material adverse

effect on our business.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at

the center of scientific discovery for more than 50 years, manufacturing

and distributing a broad range of products for the life science research

and clinical diagnostic markets. The Company is renowned worldwide among

hospitals, universities, major research institutions, as well as

biotechnology and pharmaceutical companies for its commitment to quality

and customer service. Founded in 1952, Bio-Rad is headquartered in

Hercules, California, and serves more than 85,000 research and industry

customers worldwide through its global network of operations. The Company

employs over 6,800 people globally and had revenues of nearly $1.8 billion

in 2009. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995 and Section 21E of

the Securities Exchange Act of 1934. Forward-looking statements generally

can be identified by the use of forward-looking terminology such as,

"believe," "expect," "may," "will," "intend," "estimate," "continue," or

similar expressions or the negative of those terms or expressions. Such

statements involve risks and uncertainties, which could cause actual

results to vary materially from those expressed in or indicated by the

forward-looking statements. For further information regarding the Company's

risks and uncertainties, please refer to the "Risk Factors" in the

Company's public reports filed with the Securities and Exchange Commission,

including the Company's most recent Annual Report on Form 10-K, Quarterly

Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions

you not to place undue reliance on forward-looking statements, which

reflect an analysis only and speak only as of the date hereof. Bio-Rad

Laboratories, Inc., disclaims any obligation to update these

forward-looking statements.

Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Income

(in thousands, except per share data)

(UNAUDITED)

Three Months Ended

March 31,

--------------------------

2010 2009

------------ ------------

Net sales $ 454,234 $ 400,933

Cost of goods sold 197,107 172,031

------------ ------------

Gross profit 257,127 228,902

Selling, general and administrative expense 153,617 140,313

Product research and development expense 40,263 37,152

------------ ------------

Income from operations 63,247 51,437

Interest expense 14,444 7,807

Foreign exchange gains, net (217) (774)

Other (income) expense, net (799) 1,159

------------ ------------

Income before taxes 49,819 43,245

Provision for income taxes (14,427) (11,202)

------------ ------------

Net income including noncontrolling interests 35,392 32,043

Less: Net income attributable to

noncontrolling interests (531) (1,778)

------------ ------------

Net income attributable to Bio-Rad $ 34,861 $ 30,265

============ ============

Basic earnings per share:

Net income attributable to Bio-Rad $ 1.27 $ 1.11

============ ============

Weighted average common shares 27,545 27,321

============ ============

Diluted earnings per share:

Net income attributable to Bio-Rad $ 1.24 $ 1.10

============ ============

Weighted average common shares 28,072 27,618

============ ============

Bio-Rad Laboratories, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

(UNAUDITED)

March 31, December 31,

2010 2009

------------- -------------

Current assets:

Cash and cash equivalents $ 598,134 $ 649,938

Short-term investments 93,648 94,876

Accounts receivable, net 344,989 345,734

Inventories, net 380,707 351,206

Other current assets 125,809 120,920

------------- -------------

Total current assets 1,543,287 1,562,674

Property, plant and equipment, net 313,549 302,417

Goodwill, net 335,085 327,626

Purchased intangibles, net 213,342 204,779

Other assets 141,609 138,357

------------- -------------

Total assets $ 2,546,872 $ 2,535,853

============= =============

Current liabilities:

Accounts payable $ 99,160 $ 92,988

Accrued payroll and employee benefits 106,261 126,702

Notes payable and current maturities of

long-term debt 5,104 5,132

Income and other taxes payable 41,881 42,322

Other current liabilities 145,764 152,828

------------- -------------

Total current liabilities 398,170 419,972

Long-term debt, net of current maturities 738,662 737,919

Other long-term liabilities 109,117 98,749

------------- -------------

Total liabilities 1,245,949 1,256,640

Bio-Rad stockholders' equity 1,282,187 1,259,726

Noncontrolling interests 18,736 19,487

------------- -------------

Total stockholders' equity 1,300,923 1,279,213

------------- -------------

Total liabilities and stockholders'

equity $ 2,546,872 $ 2,535,853

============= =============

Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(UNAUDITED)

Three Months

Ended March 31,

2010 2009

------------ ------------

Cash flows from operating activities:

Cash received from customers $ 445,669 $ 395,356

Cash paid to suppliers and employees (389,505) (375,628)

Interest paid (21,086) (8,775)

Income tax payments (13,279) (6,012)

Other operating activities 470 1,430

------------ ------------

Net cash provided by operating activities 22,269 6,371

Cash flows from investing activities:

Payment for acquisitions and long-term

investments (66,496) (441)

Other investing activities (10,518) (12,275)

------------ ------------

Net cash used in investing activities (77,014) (12,716)

Cash flows from financing activities:

Payments on long-term borrowings (1,595) (1,882)

Other financing activities 2,628 (161)

------------ ------------

Net cash provided by (used in) financing

activities 1,033 (2,043)

Effect of foreign exchange rate changes on cash 1,908 (3,266)

------------ ------------

Net decrease in cash and cash equivalents (51,804) (11,654)

Cash and cash equivalents at beginning of

period 649,938 204,524

------------ ------------

Cash and cash equivalents at end of period $ 598,134 $ 192,870

============ ============

Reconciliation of net income including

noncontrolling interests to net cash

provided by operating activities:

Net income including noncontrolling interests $ 35,392 $ 32,043

Adjustments to reconcile net income including

noncontrolling interests to net cash provided

by operating activities:

Depreciation and amortization 27,548 22,327

Changes in working capital (32,746) (46,871)

Other (7,925) (1,128)

------------ ------------

Net cash provided by operating activities $ 22,269 $ 6,371

============ ============


For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000

Email Contact



👍️0
locksflooring locksflooring 14 years ago
Well being your post is number 20 I never realized it was your Board and I dont remember stating I knew more about BIO than you.
👍️0
SAE SAE 14 years ago
Locksflooring,

You seem to have taken my place as moderator for this board, so you must feel that you know more about this company and possibly the industry, what are your thoughts on why this company's stock is trading today at a new 52 week high? Also, any predictions on their upcoming announcements?

GLTY,

Stockinvestor

Bio-Rad Laboratories, Inc. (BIO)
$ 111.99 ?1.87 (1.70%)
Volume: 33,248

Bid (USD) Ask (USD) Last Traded Open Prev Close
111.97 112.03 2:40:44 PM EDT 110.45 110.12
Day's Range 52-Wk Range Avg Volume EPS P/E
109.90 - 112.18 66.70 - 110.46
👍️0
locksflooring locksflooring 14 years ago
Bio-Rad to Report First-Quarter 2010 Financial Results Tuesday, May 4, 2010
Date : 04/12/2010 @ 8:00AM
Source : MarketWire
Stock : Bio-Rad Laboratories (BIO)
Quote : 107.13 0.0 (0.00%) @ 6:28AM


Bio-Rad to Report First-Quarter 2010 Financial Results Tuesday, May 4, 2010

HERCULES, CA -- (Marketwire)
04/12/10
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the first quarter 2010 on Tuesday, May 4, 2010, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

Interested parties may access the call by dialing 800-599-9829 (in the U.S.) or 617-847-8703 (international), access number 91876357.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 68368901, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, please visit www.bio-rad.com.


For more information, please contact:

Christine Tsingos, Vice President and Chief Financial Officer, or

Ron Hutton, Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000

Email Contact



👍️0
locksflooring locksflooring 14 years ago
Bio-Rad Reports Record Fourth-Quarter and Full-Year 2009 Financial Results
Date : 02/24/2010 @ 4:24PM
Source : MarketWire
Stock : Bio-Rad Laboratories (BIO)
Quote : 97.97 1.03 (1.06%) @ 4:48PM


Bio-Rad Reports Record Fourth-Quarter and Full-Year 2009 Financial Results
HERCULES, CA -- (Marketwire) -- 02/24/10 --

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2009.


Fourth-quarter reported revenues were $495.1 million, up 10.5% compared to $448.0 million reported for the fourth quarter of 2008. On a currency-neutral basis, quarterly revenues increased 4.3% compared to the same period last year. This increase was the result of organic growth across Bio-Rad's two main areas, Life Science and Clinical Diagnostics.

Fourth-quarter gross margin was 54.2% compared to 55.1% during the same quarter last year.


Net income attributable to Bio-Rad for the fourth quarter of 2009 was $37.9 million, or $1.35 per share on a fully diluted basis compared to ($0.30) per share, during the same period last year. The fourth quarter 2008 loss was a result of non-cash impairment charges of $35.0 million. Included in the fourth quarter of 2009 were non-cash impairment charges of $3.8 million.


For the full year, sales grew by 1.1% to $1,784.2 million compared to $1,764.4 million in 2008. After normalizing for the impact of currency effects, Bio-Rad sales grew by 5.5%.


Full-year net income attributable to Bio-Rad was $144.6 million, or $5.20 per share on a fully diluted basis, compared to $89.5 million, or $3.24 per share, respectively, in 2008. Full-year gross margin was 56.0% compared to last year's figure of 54.6%. This improvement in gross margin is primarily the result of improved manufacturing planning and utilization as well as a reduction in purchase accounting and royalty-related expenses.


"We are pleased with our performance in the fourth quarter as well as the entire year," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "We approached 2009 with caution as the world faced some tough economic conditions. Yet in spite of those challenges, 2009 turned out to be another successful year for Bio-Rad. Looking ahead to 2010, we will focus on the integration of the diagnostics businesses of Biotest AG that Bio-Rad acquired in January and the introduction of new products."

Life Science

The Life Science segment net sales for the fourth quarter were $191.0 million, up 12.1% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 6.6%.

Full-year reported revenues for the Life Science segment were $631.5 million, down 1.9% over the prior year, or an increase of 0.8% on a currency-neutral basis. Performance in the Life Science segment during the fourth quarter benefited from sales of the Company's next generation PCR instruments, in particular, the CFX96? real-time thermal cycler. Segment performance was also boosted by sales of the Company's protein separation and analysis tools including electrophoresis, chromatography, and imaging products as well as sales of the ProteOn? protein interaction array system. During the quarter, the segment launched the Mini-PROTEAN® TGX precast electrophoresis gel product line, which delivers ultra-fast time to results, high resolution, and extended shelf life.


Clinical Diagnostics

The Clinical Diagnostics segment reported net sales of $300.5 million for the fourth quarter, up 9.7% compared to the prior-year quarter. On a currency-neutral basis, net sales were up 2.9%. Full-year reported revenues for the Clinical Diagnostics segment were $1,139.9 million, an increase of 3.0% over the prior year. On a currency-neutral basis, full-year sales increased 8.5% compared to 2008 results. Performance in the Clinical Diagnostics segment during the fourth quarter was the result of growth across all product lines, most notably quality controls, blood typing, and diabetes monitoring. During the fourth quarter, Bio-Rad announced that it had signed an agreement to acquire certain diagnostics businesses of Biotest AG, including its diagnostics products in the areas of blood transfusion testing, transplantation, and infectious diseases. (The transaction was completed in the first quarter of 2010).


2009 Full-Year Highlights

-- Full-year Company sales grew by 1.1% to $1,784.2 million.

-- Full-year net income attributable to Bio-Rad was $144.6 million, or $5.20 per share on a fully diluted basis, compared to $89.5 million, or $3.24 per share, respectively, in 2008.

-- In April, the Life Science segment launched its SsoFast? EvaGreen® Supermix, the first member of Bio-Rad's next-generation family of high-performance, real-time PCR reagents.

-- In June, the Clinical Diagnostics segment announced that it had received FDA clearance of two new multiplex infectious disease serology panels for use on the BioPlex 2200 system: the BioPlex ToRC IgG panel and the BioPlex HSV-1 & HSV-2 IgG panel. The ToRC IgG kit simultaneously detects IgG class antibodies to Toxoplasma gondii (T. gondii), Rubella, and Cytomegalovirus (CMV). The HSV-1 & HSV-2 IgG kit utilizes type-specific proteins to simultaneously detect and differentiate IgG class antibodies to the two most common herpes subtypes, HSV-1 and HSV-2.

-- In September, Bio-Rad and Bruker Corporation, a manufacturer of mass spectrometry (MS) instruments, announced the launch of the Lucid Proteomics System, which improves the possibility of discovering biomarkers that have clinical relevance.

-- Also in September, Bio-Rad announced the launch of Unity Real Time® 2.0, the latest version of its expert QC Data Management solution. The platform is designed to manage laboratory QC and to validate analytical runs.

-- In October, Bio-Rad announced it had signed an agreement to acquire certain diagnostics businesses of Biotest AG, including its diagnostics products in the areas of blood transfusion testing, transplantation, and infectious diseases. (The transaction was completed in the first quarter of 2010).


Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) February 24, 2010. Interested parties may access the call by dialing 866-277-1181 (in the U.S.) or 617-597-5358 (international), access number 83859462. The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 44802116 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days.


About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,700 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit www.bio-rad.com.


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.


Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Income

(in thousands, except per share data) (UNAUDITED)

Three Months Ended Twelve Months Ended December 31, December 31, ------------------------ ------------------------ 2009 2008 2009 2008 ----------- ----------- ----------- ----------- Net sales $ 495,073 $ 447,965 $ 1,784,244 $ 1,764,365 Cost of goods sold 226,604 201,289 784,401 801,843 ----------- ----------- ----------- ----------- Gross profit 268,469 246,676 999,843 962,522

Selling, general and administrative expense 163,862 154,497 601,468 591,304 Product research and development expense 44,510 41,120 163,585 159,518 Impairment losses on goodwill and long-lived assets 3,802 28,757 3,802 28,757 ----------- ----------- ----------- ----------- Income from operations 56,295 22,302 230,988 182,943

Interest expense 14,363 7,985 47,024 32,113 Foreign exchange losses 1,754 5,238 5,003 7,634 Other (income) expense, net (1,915) 5,020 (6,871) 353 ----------- ----------- ----------- ----------- Income before taxes 42,093 4,059 185,832 142,843

Provision for income taxes (3,571) (10,567) (36,667) (44,579) ----------- ----------- ----------- ----------- Net income (loss) including noncontrolling interests 38,522 (6,508) 149,165 98,264

Less: Net income attributable to noncontrolling interests (660) (1,708) (4,545) (8,754) ----------- ----------- ----------- ----------- Net income (loss) attributable to Bio-Rad $ 37,862 $ (8,216) $ 144,620 $ 89,510 =========== =========== =========== ===========

Basic earnings (loss) per share: Net income (loss) attributable to Bio-Rad $ 1.38 $ (0.30) $ 5.28 $ 3.30 =========== =========== =========== ===========

Weighted average common shares 27,491 27,278 27,404 27,112 =========== =========== =========== ===========

Diluted earnings (loss) per share: Net income (loss) attributable to Bio-Rad $ 1.35 $ (0.30) $ 5.20 $ 3.24 =========== =========== =========== ===========

Weighted average common shares 28,006 27,278 27,828 27,638 =========== =========== =========== ===========

Bio-Rad Laboratories, Inc.

Condensed Consolidated Balance Sheets

(In thousands) (UNAUDITED)

December 31, December 31, 2009 2008 ----------- ----------- Current assets: Cash and cash equivalents $ 649,938 $ 204,524 Short-term investments 94,876 38,950 Accounts receivable, net 345,734 339,653 Inventories 351,206 375,616 Other current assets 120,920 135,198 ----------- ----------- Total current assets 1,562,674 1,093,941

Property, plant and equipment, net 302,417 300,732 Goodwill, net 327,626 321,820 Purchased intangibles, net 204,779 228,590 Other assets 138,357 92,181 ----------- ----------- Total assets $ 2,535,853 $ 2,037,264 =========== ===========

Current liabilities: Accounts payable $ 92,988 $ 117,982 Accrued payroll and employee benefits 126,702 119,420 Notes payable and current maturities of long-term debt 5,132 9,578 Income and other taxes payable 42,322 33,731 Other current liabilities 152,828 137,323 ----------- ----------- Total current liabilities 419,972 418,034

Long-term debt, net of current maturities 737,919 445,979 Other long-term liabilities 98,749 102,611 ----------- ----------- Total liabilities 1,256,640 966,624

Bio-Rad stockholders' equity 1,259,726 1,041,139 Noncontrolling interests 19,487 29,501 ----------- ----------- Total stockholders' equity 1,279,213 1,070,640 ----------- ----------- Total liabilities and stockholders' equity $ 2,535,853 $ 2,037,264 =========== ===========

Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands) (UNAUDITED)

Year Ended December 31,

2009 2008 ----------- -----------

Cash flows from operating activities: Cash received from customers $ 1,778,316 $ 1,765,667 Cash paid to suppliers and employees (1,386,382) (1,495,669) Interest paid (38,471) (30,792) Income tax payments (37,749) (49,159) Other operating activities 9,360 1,324 ----------- ----------- Net cash provided by operating activities 325,074 191,371

Cash flows from investing activities: Payment for acquisitions and long-term investments (35,990) (53,014) Other investing activities (139,962) (93,093) ----------- ----------- Net cash used in investing activities (175,952) (146,107)

Cash flows from financing activities: Long-term borrowings 294,750 1,600 Payments on long-term borrowings (6,823) (11,589) Other financing activities 6,006 16,320 ----------- ----------- Net cash provided by financing activities 293,933 6,331

Effect of foreign exchange rate changes on cash 2,359 (8,835) ----------- -----------

Net increase in cash and cash equivalents 445,414 42,760 Cash and cash equivalents at beginning of year 204,524 161,764 ----------- ----------- Cash and cash equivalents at end of year $ 649,938 $ 204,524 =========== ===========

Reconciliation of net income including noncontrolling interests to net cash provided by operating activities:

Net income including noncontrolling interests $ 149,165 $ 98,264 Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: Depreciation and amortization 101,682 97,088 Impairment losses on goodwill and long-lived assets 3,802 28,757 Changes in working capital 66,707 (46,563) Other 3,718 13,825 ----------- ----------- Net cash provided by operating activities $ 325,074 $ 191,371 =========== ===========

For more information contact: Christine Tsingos Vice President and Chief Financial Officer Ron Hutton Treasurer Bio-Rad Laboratories, Inc.

510-724-7000 Email Contact


👍️0
locksflooring locksflooring 14 years ago
Bio-Rad Laboratories, Inc. Announces Completion of Exchange Offer
Date : 02/04/2010 @ 7:45PM
Source : MarketWire
Stock : Bio-Rad Laboratories (BIO)
Quote : 92.75 -1.72 (-1.82%) @ 8:00PM


Bio-Rad Laboratories, Inc. Announces Completion of Exchange Offer




HERCULES, CA -- (Marketwire) -- 02/04/10 --

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced that it has completed its offer to exchange (the "Exchange Offer") up to $300 million aggregate principal amount of its 8.00% Senior Subordinated Notes due 2016 that have been registered under the Securities Act of 1933, as amended, for any and all of its outstanding 8.00% Senior Subordinated Notes due 2016 that were issued in a private placement (the "Private Notes"). All of the outstanding $300 million aggregate principal amount of the Private Notes were tendered and received prior to the expiration of the Exchange Offer at 5:00 p.m., New York City time, on February 4, 2010



This press release shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities. The Exchange Offer was made only by means of a written prospectus dated December 29, 2009


About Bio-Rad


Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,700 people globally and had revenues exceeding $1.7 billion in 2008. For more information, please visit www.bio-rad.com


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements


For more information contact: Christine Tsingos Vice President and Chief Financial Officer or Ron Hutton Treasurer Bio-Rad Laboratories, Inc

510-724-7000 Email Contact

👍️0
locksflooring locksflooring 14 years ago
Bio-Rad to Report Fourth-Quarter and Full-Year 2009 Financial Results Wednesday, February 24, 2010
Date : 01/27/2010 @ 7:18PM
Source : MarketWire
Stock : Bio-Rad Laboratories (BIO)
Quote : 94.91 0.33 (0.35%) @ 8:00PM


Bio-Rad to Report Fourth-Quarter and Full-Year 2009 Financial Results Wednesday, February 24, 2010




HERCULES, CA -- (Marketwire) -- 01/27/10 --

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2009 on Wednesday, February 24, 2010, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day


Interested parties may access the call by dialing 866-277-1181 (in the U.S.) or 617-597-5358 (international), access number 83859462. The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 44802116 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days



About Bio-Rad


Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,700 people globally and had revenues exceeding $1.7 billion in 2008

For more information, please visit www.bio-rad.com


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements


For more information contact: Christine Tsingos Vice President and Chief Financial Officer or Ron Hutton Treasurer Bio-Rad Laboratories, Inc

510-724-7000 Email Contact

👍️0
SAE SAE 14 years ago
Bio-Rad Completes the Purchase of Certain Diagnostics Businesses of Biotest AG

HERCULES, CA -- (Marketwire) -- 01/06/10 --

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has completed the purchase of certain diagnostics businesses of Biotest AG, including its diagnostics products in the areas of blood transfusion testing, transplantation, and infectious diseases for 45 million euros

Bio-Rad signed a definitive agreement to acquire these diagnostics businesses of Biotest on October 23, 2009


"We are pleased with the opportunity to expand our product offering in the area of immunohematology," said Norman Schwartz, Bio-Rad President and CEO

"Integrating Biotest diagnostics products into our current offering will further strengthen Bio-Rad's position in this area and enable us to provide our customers, including those in the U.S., with a broader range of products and services."



About Bio-Rad


Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com


About Biotest


Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as reagents and systems for microbiology. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. The products of the Microbiological Monitoring segment are primarily used in hygiene monitoring. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities

and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements


For more information contact: Bio-Rad Laboratories, Inc

Tina Cuccia Corporate Communications 510-724-7000 Email Contact

Biotest AG Dr. Monika Buttkereit +49 (0) 6103 801-4406 Email Contact

http://ih.advfn.com/p.php?pid=nmona&cb=1262895164&article=40983335&symbol=NY%5EBIO
👍️0
SAE SAE 14 years ago
Axis-Shield and Bio-Rad Announce Launch of New Anti-CCP Test for Bio-Rad's BioPlex 2200 System

HERCULES, CA and DUNDEE, SCOTLAND -- (Marketwire) -- 01/05/10 --

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc (LSE: ASD) (OSE: ASD), an international in-vitro diagnostics (IVD) company, today announced the launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis. The assay, which will run on Bio-Rad's BioPlex® 2200 system, measures anti-CCP (anti-cyclic citrullinated peptide antibodies), a novel marker that has been shown to have superior specificity in the diagnosis of rheumatoid arthritis. The BioPlex 2200 Anti-CCP kit is based on Axis-Shield's proprietary anti-CCP technology. The assay is available for sale in certain countries outside the U.S



"The anti-CCP testing market is one of the fastest growing markets in autoimmune diagnostics," said John Goetz, Bio-Rad Vice President and Group Manager of Clinical Diagnostics. "The addition of this assay will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system."


"We are very pleased that Bio-Rad has reached this important commercial milestone in our agreement and believe that availability on the BioPlex system will help expand the market for this important early marker for this debilitating condition," said Ian Gilham, Axis-Shield CEO. "The measurement of these antibodies has recently been cited as a key parameter in the definitive diagnosis of rheumatoid arthritis by the influential American College of Rheumatology."


The BioPlex 2200 system is a fully automated, random-access multiplex testing platform with an assay menu targeting autoimmune diagnostics and infectious diseases. In the U.S., the BioPlex 2200 Anti-CCP kit is pending clearance by the FDA


About Bio-Rad


Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com


About Axis-Shield


Axis-Shield is an international in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specialises in the supply of instruments and tests for the rapidly growing physician's office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, and diabetes. For more information on Axis-Shield, please refer to www.axis-shield.com


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements


For more information contact:

Bio-Rad Laboratories, Inc

Tina Cuccia Corporate Communications 510-724-7000 Email Contact

Axis-Shield plc Ian Gilham Chief Executive Officer Ronny Hermansen Financial Director +44 (0) 203 178 7849 Jonathan Birt/Mo Noonan +44 (0) 207 831 3113

http://ih.advfn.com/p.php?pid=nmona&cb=1262894639&article=40959959&symbol=NY%5EBIO

👍️0
SAE SAE 14 years ago
Bio-Rad Laboratories, Inc. Announces Commencement of Exchange Offer of Its 8.00% Senior Subordinated Notes Due 2016 for Register

HERCULES, CA -- (Marketwire) -- 12/29/09 --

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced that it has commenced a registered exchange offer to exchange up to $300 million aggregate principal amount of its 8.00% Senior Subordinated Notes due 2016 which have been registered under the Securities Act of 1933, as amended (the "Exchange Notes"), for any and all of its outstanding 8.00% Senior Subordinated Notes due 2016 which were issued in a private placement (the "Private Notes")



The sole purpose of the exchange offer is to fulfill the obligations of Bio-Rad with respect to the registration of the Private Notes. Pursuant to a registration rights agreement entered into by Bio-Rad in connection with the sale of the Private Notes, Bio-Rad agreed to file with the Securities and Exchange Commission a registration statement relating to the exchange offer pursuant to which the Exchange Notes, containing substantially identical terms to the Private Notes, would be offered in exchange for Private Notes that are tendered by the holders of those notes


Any Private Notes not tendered for exchange in the exchange offer will remain outstanding and continue to accrue interest, but will not retain any rights under the registration rights agreement except in limited circumstances


The terms of the exchange offer are contained in the exchange offer prospectus


The exchange offer will expire at 5:00 PM, New York City time, on January 28, 2010, unless extended. Private Notes tendered pursuant to the exchange offer may be withdrawn at any time prior to the expiration date by following the procedures set forth in the exchange offer prospectus


Requests for assistance or for copies of the exchange offer prospectus should be directed to Wells Fargo Bank, National Association, the exchange agent, at 625 Marquette Avenue, MAC CODE: N9303-121, Minneapolis, Minnesota 55402, Attention: Corporate Trust Administration, 800-344-5128


This press release shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities. The exchange offer will be made only by means of a written prospectus


This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the exchange offer prospectus and in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K

The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements


For more information contact: Christine Tsingos, Vice President and Chief Financial Officer, or Ron Hutton, Treasurer Bio-Rad Laboratories, Inc

510-724-7000 Email Contact

http://ih.advfn.com/p.php?pid=nmona&cb=1262160795&article=40911235&symbol=NY%5EBIO
👍️0
SAE SAE 14 years ago

Coverage initiated on Bio-Rad Labs by Maxim Group

http://finance.yahoo.com/q/ud?s=BIO
👍️0
SAE SAE 14 years ago


- Current report filing (8-K)


Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.




Mr. Ruediger Naumann-Etienne resigned as a member of the Board of Directors

(the “Board”) of Bio-Rad Laboratories, Inc. (the “Company”) effective December 4, 2009. Mr. Naumann-Etienne was an independent director and a member of the Audit and Compensation Committees of the Board. Mr. Naumann-Etienne’s resignation is not related to any disagreement with the Company’s operations, policies or practices.

On December 9, 2009, the Company notified the New York Stock Exchange (“NYSE”) that the Company does not comply with the audit committee composition requirements under Section 303A.07(a) of the NYSE Listed Company Manual as a result of the resignation of Mr. Naumann-Etienne. This resignation left the Company with only two independent directors serving on its Audit Committee rather than the requisite three independent directors. The Company is currently seeking a replacement for Mr. Naumann-Etienne to serve on the Board and the Audit Committee of the Board and intends to regain compliance with the requirements of Section 303A.07(a) of the NYSE Listed Company Manual as soon as practicable.

http://ih.advfn.com/p.php?pid=nmona&cb=1260430189&article=40706136&symbol=NY%5EBIO
👍️0
SAE SAE 14 years ago
Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education

Vernier's experience in data analysis combined with Bio-Rad's Biotechnology Explorer (TM) program kits and curricula provide state-of-the-art solutions to biotechnology education

BEAVERTON, Ore., Nov. 18 /PRNewswire/ -- Vernier Software & Technology, a provider of educational science interfaces, sensors, and software and Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products that include its Biotechnology Explorer(TM) program, are combining their respective expertise in science education products to offer an enhanced biotechnology curricula for educators as well as students at the high school and college-level.

The newly combined curriculum will bring together Vernier's instructor-friendly data-acquisition equipment with Bio-Rad's industry-standard Biotechnology Explorer program kits and equipment. An example of the curriculum being developed features instructional tools that allow teachers to utilize Bio-Rad's lab activities for bacterial transformation and DNA electrophoresis in conjunction with Vernier's Blue and White Digital Bioimaging Systems and Logger Pro Software.

"Students need a real-world, high-end lab experience to learn these complex concepts," said David Vernier, Vernier co-founder and a former physics teacher. "This partnership combines the expertise of both organizations to create lab experiences that are easy for instructors to implement. We believe partnering with Bio-Rad will allow us to better meet the needs of life science instructors at the high school and college levels."

Vernier and Bio-Rad are currently offering workshops on their new solutions and presented a joint workshop at the National Association of Biology Teachers (NABT) conference in Denver in November 2009. For more information about these events, visit http://www.vernier.com/workshops.

About Vernier Software & Technology

Vernier Software & Technology has been an innovator of data-collection technology for 28 years. Creating easy-to-use and affordable science interfaces, sensors, and software, their products can be found in education from elementary school to college. Vernier helps teachers enhance their science curriculum, increase learning, and build students' critical thinking skills. Vernier's technologies are in use worldwide in more than 125 countries. For more information visit http://www.vernier.com/.

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (NYSE:BIONYSE:andNYSE:BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, please visit http://www.bio-rad.com/.

DATASOURCE: Vernier Software & Technology


CONTACT: Daylene Long, Vernier Software & Technology, +1-503-277-2299,

; Julie Mathern, Bio-Rad Laboratories, +1-510-741-6347,

; Kati Elliott, KEH Communications, +1-410-975-9638,



Web Site: http://www.vernier.com/

http://www.bio-rad.com/


http://ih.advfn.com/p.php?pid=nmona&cb=1259128408&article=40422799&symbol=NY%5EBIO
👍️0
SAE SAE 14 years ago
Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 11 Percent

HERCULES, CA -- (Marketwire) -- 11/03/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2009.

Third-quarter reported revenues were $461.1 million, up 4.4% compared to $441.8 million reported for the third quarter of 2008. On a currency-neutral basis, quarterly revenues increased 11.1% compared to the same period last year. This improvement is primarily the result of organic growth across a range of products in Bio-Rad's two main areas, Life Science and Clinical Diagnostics as well as the additional revenue generated from the purchase of certain DiaMed distributors since the third quarter of 2008.

Net income attributable to Bio-Rad for the third quarter was $38.5 million, or $1.38 per share on a fully diluted basis, compared to $27.8 million or $1.00 per share, respectively, during the same period last year.

Third-quarter gross margin increased to 56.5% compared to 54.4% during the same quarter last year.

Year-to-date revenues were $1.3 billion, down 2.1% compared to the first three quarters in 2008. Adjusting for the impact of currency effects, revenue growth was 5.9%. Year-to-date net income attributable to Bio-Rad for 2009 was $106.8 million, or $3.85 per share on a fully diluted basis, compared to $97.7 million, or $3.54 per share, respectively, during the same period in 2008.

"We are pleased with the results of the third-quarter, which show continued strength in many of our product areas," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "As we had expected, the economy continued to have somewhat of a negative impact on customer spending particularly in our Life Science segment, but we are encouraged by the resiliency we've seen in many of our markets."



Life Science



The Life Science segment net sales for the third quarter were $150.4 million, down 4.1% or 0.4% on a currency-neutral basis, compared to the same period last year. Sales across a number of product lines in the Life Science segment performed well during the quarter, in particular, process chromatography and gene expression products. Performance of the segment also benefited from sales of the Company's ProteOn(TM) protein interaction array system, as many customers began to order additional instruments.

Growth in the Life Science segment was negatively impacted by slowed research markets in both the U.S. and Europe, which reflect constraint and delays in spending by academic and biopharmaceutical customers. In September, Bio-Rad and Bruker Corporation (NASDAQ: BRKR), a manufacturer of mass spectrometry (MS) instruments, announced the launch of the Lucid Proteomics System, which improves the possibility of discovering biomarkers that have clinical relevance.




Clinical Diagnostics



The Clinical Diagnostics segment reported net sales of $307.5 million for the third quarter, up 9.3% compared to the third quarter in 2008. On a currency-neutral basis, sales for the segment increased 17.8%. These gains are the result of strong sales across a number of product lines, including blood virus testing products, quality control products, and the Company's BioPlex® 2200 system. The segment also benefited from additional revenue resulting from the purchase of certain DiaMed European distributors in the fourth quarter of 2008, as well as the purchase of the DiaMed distributor in India in the second quarter of this year. In September, Bio-Rad announced the launch of Unity Real Time® 2.0, the latest version of its expert QC Data Management solution. The platform is designed to manage laboratory QC and to validate analytical runs.




Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 3, 2009. Interested parties may access the call by dialing 866-700-7173 (in the U.S.) or 617-213-8838 (international), access number 78653201.




The live webcast may also be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 96529078 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days.




About Bio-Rad



Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations.

The Company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, please visit www.bio-rad.com.




This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.





Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Income (in thousands, except per share data)
(UNAUDITED) Three Months Ended Nine Months Ended
September 30, September 30,
------------------ ----------------------
2009 2008 2009 2008
-------- -------- ---------- ----------
Net sales $461,055 $441,842 $1,289,171 $1,316,400
Cost of goods sold 200,545 201,300 557,797 600,554
-------- -------- ---------- ----------
Gross profit 260,510 240,542 731,374 715,846Selling, general and
administrative expense 153,623 150,518 437,606 436,807
Research and development
expense 39,516 38,830 119,075 118,398
-------- -------- ---------- ----------
Income from operations 67,371 51,194 174,693 160,641Interest expense 14,487 8,180 32,661 24,128
Foreign exchange losses, net 1,472 91 3,249 2,396
Other (income) expense, net 192 (523) (4,956) (4,667)
-------- -------- ---------- ----------
Income before taxes 51,220 43,446 143,739 138,784Provision for income taxes (11,920) (12,557) (33,096) (34,012)
-------- -------- ---------- ----------
Net income including
noncontrolling interests 39,300 30,889 110,643 104,772
Less: Net income
attributable to
noncontrolling
interests (776) (3,056) (3,885) (7,046)
-------- -------- ---------- ----------Net income attributable to
Bio-Rad $ 38,524 $ 27,833 $ 106,758 $ 97,726
======== ======== ========== ==========Basic earnings per share:
Net income attributable to
Bio-Rad $ 1.40 $ 1.02 $ 3.90 $ 3.61
======== ======== ========== ========== Weighted average common
shares 27,431 27,171 27,375 27,055
======== ======== ========== ==========Diluted earnings per share:
Net income attributable to
Bio-Rad $ 1.38 $ 1.00 $ 3.85 $ 3.54
======== ======== ========== ========== Weighted average common
shares 27,875 27,747 27,749 27,619
======== ======== ========== ==========
Bio-Rad Laboratories, Inc. Condensed Consolidated Balance Sheets (In thousands)
(UNAUDITED) September 30, December 31,
2009 2008
------------- -------------
Current assets:
Cash and cash equivalents $ 554,179 $ 204,524
Short-term investments 87,930 38,950
Accounts receivable, net 350,762 339,653
Inventories, net 383,896 375,616
Other current assets 126,634 135,198
------------- -------------
Total current assets 1,503,401 1,093,941Net property, plant and equipment 305,921 300,732
Goodwill 327,469 321,820
Purchased intangibles, net 216,730 228,590
Other assets 124,685 92,181
------------- -------------
Total assets $ 2,478,206 $ 2,037,264
============= =============
Current liabilities:
Notes payable and current maturities of
long-term debt $ 5,346 $ 9,578
Accounts payable 92,381 117,982
Accrued payroll and employee benefits 118,891 119,420
Sales, income and other taxes payable 53,810 33,731
Other current liabilities 145,267 137,323
------------- -------------
Total current liabilities 415,695 418,034Long-term debt, net of current maturities 738,687 445,979
Other long-term liabilities 96,153 102,611
------------- -------------
Total liabilities 1,250,535 966,624Bio-Rad stockholders' equity 1,208,661 1,041,139
Noncontrolling interests 19,010 29,501
------------- -------------
Total stockholders' equity 1,227,671 1,070,640
------------- -------------
Total liabilities and stockholders'
equity $ 2,478,206 $ 2,037,264
============= =============
Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Cash Flows (In thousands)
(UNAUDITED) Nine Months Ended
September 30,
2009 2008
----------- -----------Cash flows from operating activities:
Cash received from customers $ 1,291,054 $ 1,318,003
Cash paid to suppliers and employees (1,030,153) (1,152,538)
Interest paid (31,511) (24,141)
Income tax payments (27,746) (31,053)
Other operating activities 7,708 2,759
----------- -----------
Net cash provided by operating activities 209,352 113,030Cash flows from investing activities:
Payments for acquisitions and long-term
investments (35,937) (18,069)
Other investing activities (117,424) (63,799)
----------- -----------
Net cash used in investing activities (153,361) (81,868)Cash flows from financing activities:
Payments on long-term debt (5,253) (9,349)
Long-term borrowings 294,750 -
Other financing activities 2,766 13,758
----------- -----------
Net cash provided by financing activities 292,263 4,409Effect of exchange rate changes on cash 1,401 (3,708)
----------- -----------Net increase in cash and cash equivalents 349,655 31,863
Cash and cash equivalents at beginning of period 204,524 161,764
----------- -----------
Cash and cash equivalents at end of period $ 554,179 $ 193,627
=========== ===========
Reconciliation of net income including
noncontrolling interests to net cash provided
by operating activities:Net income including noncontrolling interests $ 110,643 $ 104,772
Adjustments to reconcile net income including
noncontrolling interests to net cash provided
by operating activities:
Depreciation and amortization 74,003 74,322
Changes in working capital 23,583 (67,670)
Other 1,123 1,606
----------- -----------
Net cash provided by operating activities $ 209,352 $ 113,030
=========== ===========



For more information contact:

Christine Tsingos, Vice President and Chief Financial Officer, or

Ron Hutton, Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000
http://ih.advfn.com/p.php?pid=nmona&cb=1257449580&article=40191531&symbol=NY%5EBIO

👍️0
SAE SAE 14 years ago
Bio-Rad Signs Agreement to Acquire Certain Diagnostics Businesses of Biotest AG

HERCULES, CA -- (Marketwire) -- 10/23/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed an agreement to acquire certain diagnostic businesses of Biotest AG for 45 million euros. The terms of the agreement were not disclosed at this time. The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2010.

Based in Germany, Biotest develops, manufactures, and markets pharmaceutical, biotherapeutic, and diagnostic products. Integrating Biotest's diagnostic business into Bio-Rad's product portfolio will broaden the company's offering in the area of immunohematology and provide Bio-Rad access to the U.S. markets with a full range of products. Biotest is listed on the SDAX on the Frankfurt Stock Exchange and has more than 2,000 employees worldwide.

"Biotest has an impressive reputation for offering quality products and customer service, and we believe their array of products in the area of immunohematology will fit in well with Bio-Rad's existing diagnostics business," said Norman Schwartz, Bio-Rad President and CEO.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.


For more information contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia

Corporate Communications

510-724-7000
http://ih.advfn.com/p.php?pid=nmona&cb=1256614851&article=40031628&symbol=NY%5EBIO

👍️0
SAE SAE 15 years ago
Bio-Rad to Report Third-Quarter 2009 Financial Results Tuesday, November 3, 2009

HERCULES, CA -- (Marketwire) -- 10/12/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the third quarter 2009 on Tuesday, November 3, 2009, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.


Interested parties can access the call by dialing 866-700-7173 (in the U.S.) or 617-213-8838 (international), access number 78653201. The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 96529078 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days.




About Bio-Rad



Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.


For more information contact:

Christine Tsingos

Vice President and Chief Financial Officer

or

Ron Hutton

Treasurer

Bio-Rad Laboratories, Inc.

510-724-7000
http://ih.advfn.com/p.php?pid=nmona&cb=1255959561&article=39853304&symbol=NY%5EBIO

👍️0
SAE SAE 15 years ago
It has certainly been awhile for Forbes (or anyone else for that matter to do an article on BIO, imo), but here is what I found as the most recent coverage. It is worth reading and studying in my opion as a baseline of their financials. Stockinvestor
http://www.forbes.com/business/lists/2009/88/bigcompanies08_Bio-Rad-Laboratories_AMZE.html

The 400 Best Big Companies
Bio-Rad Laboratories
12.22.08, 06:00 PM EST

1st time on list
http://www.bio-rad.com
👍️0
SAE SAE 15 years ago
Bio-Rad Helps Raise $1.1 Million in Napa Valley Tour de Cure



HERCULES, CA -- (Marketwire) -- 08/31/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, helped raise approximately $1.1 million during the Napa Valley Tour de Cure, which took place on May 3 to benefit the American Diabetes Association.

As the Presenting Sponsor at this year's Napa Valley Tour de Cure, Bio-Rad's "friends and family" team of 146 riders was the largest of the 162 teams participating in the Napa Valley event. Bio-Rad riders raised $73,055, exceeding its total last year of $66,500, setting a new company record. The team was also named one of the Top 10 fundraising teams in the U.S. Bio-Rad also hosted teams in Long Beach, California, and Redmond, Washington. The Tour de Cure is a series of 80 cycling events that occur each year in different locations across the United States.




"Bio-Rad looks forward to Tour de Cure each year," said Bio-Rad President Norman Schwartz. "It is wonderful to see that we exceeded our fundraising goal this year. I'd like to recognize all of the event's participants, all over the U.S. By supporting events such as Tour de Cure, we are helping to improve the lives of those suffering from diabetes."

That is a very nice thing to read, in my humble opinion! I had
a good friend with diabetes...Stockinvestor



About Bio-Rad



Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.


For more information, contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia

Corporate Communications Manager

510-724-7000


👍️0
buhg1b buhg1b 16 years ago
Bio-Rad Releases Detailed Brochure on its Bio-Plex Suspension Array System

HERCULES, Calif.- April 28, 2008 - Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of a product brochure on its BioPlexR suspension array system.

Entitled "Bio-Plex Suspension Array System", the 22-page product brochure covers features and benefits of the Bio-Plex system including workstation software, assay development tools, and the various Bio-Plex ProT assays. The brochure provides detailed lists of all of its available assays for the system in addition to ordering information.

The Bio-Plex suspension array system is a powerful array technology platform that offers reliable multiplex assays. The system is composed of all of the products necessary for a complete workflow, from sample preparation reagents and diluents to sophisticated data analysis software. The fully integrated system can enable protein and nucleic acid researchers to analyze up to 100 biomolecules in a single sample, with accurate reproducible assay results.

The assays are multiplexable bead-based assays based on xMAP technology and optimized for the Bio-Plex suspension array system. The assays and associated products include cytokines, chemokines, growth factors, diabetes, acute phase, angiogenesis, phosphoproteins, and isotyping.

Bio-Plex assays can also be run on the Luminex 100 or 200 systems.

Availability

The brochure is available either from a local Bio-Rad sales office or it can be requested by visiting the Bio-Rad web site at http://www.bio-rad.com/bio-plexassays.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.

For more information contact:

Emily C. Dale

Bio-Rad Laboratories, Inc.

510-741-6571

Emily_Dale@bio-rad.com
👍️0
buhg1b buhg1b 16 years ago
Chembio Signs Exclusive DPP(TM) Development Agreement With Bio-Rad Laboratories, Inc.
Wednesday April 16, 8:30 am ET

MEDFORD, NY--(MARKET WIRE)--Apr 16, 2008 -- Chembio Diagnostics, Inc. (OTC BB:CEMI.OB - News) ("Chembio" or the "Company") announced today that it has signed an exclusive development agreement with Bio-Rad Laboratories, Inc. ("Bio-Rad") (AMEX:BIO - News) and (AMEX:BIO-B - News) to develop a multiplex test employing Chembio's patented DPP(TM) Dual Path Platform test system. The test would also employ certain proprietary reagents belonging to Bio-Rad. The agreement contemplates that the parties would enter into a limited exclusive license to the DPP(TM) technology. Bio-Rad would have exclusive marketing rights for the product.

According to Chembio Chief Executive Officer Larry Siebert, "This collaboration with a world market leader like Bio-Rad is a good fit for Chembio, as it allows us to leverage our DPP intellectual property with our experience in product development and regulated manufacturing to develop a product to be marketed by a leading diagnostics company."

ABOUT DPP

The Dual Path Platform immunoassay is a recent Chembio innovation in the field of rapid testing for which the company received a U.S. patent in 2007. DPP(TM) technology employs two separate and distinct membrane strips, one for the sample migration and one for the test reagents. This unique dual-flow design allows for improved control and management of the sample flow. As a result, the immunological reaction is more efficient than lateral flow tests based upon studies performed by Chembio.

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of proprietary rapid diagnostic tests, participates in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third-party company. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform (DPP(TM)) technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP(TM). Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.


Contact:

Company Contact:
Chembio Diagnostics, Inc.
Susan Norcott
(631) 924-1135, ext. 125
(http://www.chembio.com)


Source: Chembio Diagnostics, Inc.
👍️0
buhg1b buhg1b 16 years ago
Bio-Rad Laboratories, Inc. Q4 2007 Earnings Call Transcript

...

Christine A. Tsingos, Chief Financial Officer, Vice President

Today we will review the fourth quarter and full-year financial results for 2007, the impact of our DiaMed acquisition, as well as provide some insight into our thinking for 2008. We know this is a lot of information and I’ll do my best to walk through it slowly.

Let’s start with a review of the quarterly results. Net sales for the fourth quarter of fiscal 2007 were $459.7 million, an increase of more than 28% versus the year-ago period sales of $343.1 million. These quarterly sales include approximately $62 million contributed by the DiaMed business.

Excluding DiaMed, sales in the fourth quarter grew 16% compared to last year, to $397.7 million. On an organic, currency-neutral basis, sales for the quarter grew 9%. This strong year-over-year growth was fueled by solid performance in both Life Sciences and Clinical Diagnostics.

During the quarter we posted record sales with in our Life Sciences group. This growth was the result of increased sales of Protein Expression, amplification and processed chromatography products. Diagnostics also posted a record quarter even before the inclusion of DiaMed which is a reflection of strong performance in blood virus, clinical systems and quality control.

Consolidated gross margin for the quarter was a reported 50.8% which includes more then $3 million of amortization expense related to the DiaMed transaction and another $3 million of foregone profit margin as required under purchase accounting. The gross margin for the base Bio-Rad business came in as expected at 53.4% as product mix in our fourth quarter typically shifts toward lower margin instrument sales.

SG&A expense for the fourth quarter was $163 million or 35.5% of sales. This represents a significant increase from just last quarter but it is important to note that the inclusion of DiaMed in our consolidated results constitutes more than $20 million of that increase. In addition approximately $2 million of amortization expense related to the deal, $8 million of negative foreign currency affect and increased selling costs, commissions and bonuses associated with the strong top-line growth also contributed to this sequential rise...(cont'd)

http://seekingalpha.com/article/68934-bio-rad-laboratories-inc-q4-2007-earnings-call-transcript?source=yahoo
👍️0
buhg1b buhg1b 16 years ago
Bio-Rad Reports Fourth-Quarter and Full-Year 2007 Financial Results
Marketwire
February 28, 2008: 04:08 PM EST

Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2007.

Fourth-quarter revenues were $459.7 million, up 34.0% compared to $343.1 million reported for the fourth quarter of 2006. This increase was due to a combination of organic growth across Bio-Rad's two main product areas, the Life Science and Clinical Diagnostics segments, as well as the addition of DiaMed Holding AG products to the Company's portfolio in the fourth quarter, which resulted in additional revenue of $62.0 million and impacted fourth-quarter and full-year results. Excluding the revenue from the DiaMed acquisition, fourth-quarter revenues were up 15.9%, or 9.0% on a currency-neutral basis, compared to the same quarter last year.

Net income for the fourth quarter was $12.4 million compared to $16.6 million during the fourth quarter last year. These results reflect non-cash charges of $12.9 million, which includes a one-time charge of $7.7 million for purchased in-process R&D, and approximately $5.2 million in amortization of intangibles related to DiaMed. Including the DiaMed acquisition, fourth-quarter basic earnings from operations were $0.46 per share, or $0.45 per share on a diluted basis, compared to $0.63 and $0.61, respectively, during the same period last year. Fourth-quarter gross margin was 50.8% compared to 54.1% during the same quarter last year. The lower margin in the most recent quarter reflects the impact of the DiaMed acquisition including foregone profit margin and the amortization of intangibles.

For the full year, sales grew by 14.7% to $1,461.1 million compared to $1,273.9 million in 2006. Excluding revenue from the DiaMed acquisition, Bio-Rad sales grew by 9.8%, or 5.2% after normalizing for the impact of currency effects. Year-over-year net income was $93.0 million, or $3.41 per share on a diluted basis, compared to $103.3 million, or $3.83 per share, respectively, in 2006. Full-year gross margin was 54.2% compared to last year's figure of 55.9%. Revenues, earnings, and gross margin for 2006 were all favorably impacted by one-time additional revenue of $11.7 million which was the result of a licensing settlement agreement reached with bioMérieux SA in 2006.

"Operationally, 2007 was another year of progress for Bio-Rad and one of investment as we welcomed DiaMed Holding AG into our organization," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "As 2008 moves forward, we will continue to explore opportunities to expand our business and improve our operational efficiencies."

Life Science

The Life Science segment net sales for the fourth quarter were $184.5 million, up 16.1% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 9.4%. Full-year reported revenues for the Life Science segment were $615.1 million, up 6.9% over the prior year, or 2.7% on a currency-neutral basis. Performance in this segment was boosted by sales of the ProteOn(TM) protein interaction array system, the Bio-Plex® suspension array system and reagents, as well as the ProteinChip® SELDI system. Bio-Plex sales continue to be positively impacted by 57 new assays that were introduced in 2006. Sales of process chromatography media and hardware were strong as the products continued to gain broad market acceptance. These materials are used during the purification stages in the manufacture of a variety of pharmaceuticals with a particular applicability to monoclonal antibody-based medicines. Growth in the Life Science segment was negatively impacted by a drop in BSE (bovine spongiform encephalopathy) testing revenues as both the number of animals tested and the average selling price continues to decline. During the fourth quarter, the segment introduced its next generation polymerase chain reaction (PCR) instruments, which are based on the new 1000-series thermal cycling platform, as well as the ProteoMiner(TM) protein enrichment kits, which provide researchers a way to concentrate and enrich low-and medium-abundance proteins that cannot be detected through traditional methods.

Clinical Diagnostics

The Clinical Diagnostics segment reported net sales of $271.4 million for the fourth quarter, up 50.7% compared to the prior-year quarter. Excluding revenue from the DiaMed acquisition, net sales were up 16.3%, or 9.0% on a currency-neutral basis, from the same period last year. Full-year reported revenues for the Clinical Diagnostics segment were $832.2 million, a 21.5% increase compared to 2006 results. Excluding revenue from the DiaMed acquisition, net sales increased 12.5%, or 7.4% net of currency effects, compared to 2006 results. These results were largely due to continued growth across all product lines, most notably quality controls, autoimmune, diabetes, clinical microbiology, as well as the BioPlex® 2200 system, a revolutionary instrument for the diagnostic laboratory that is continuing to gain market acceptance. In October, the Clinical Diagnostics segment finalized the acquisition of DiaMed Holding AG, a Swiss-based company that develops, manufactures, and markets a complete line of reagents and instruments used in blood typing and screening. Also during the quarter, the segment introduced to the U.S. market, the MRSASelect(TM) test, a chromogenic medium that detects methicillin-resistant Staphylococcus aureus, as well as its in2it(TM) analyzer for the "point-of-care" diabetes market. The in2it analyzer measures A1C, combining laboratory-accurate test results with patient convenience.

2007 Full Year Highlights

-- Full-year Company sales grew by 14.7% to $1,461.1 million.
-- Year-over-year net income was $93.0 million, compared to $103.3
million reported in 2006.
-- In October, the Company purchased 86% of the outstanding stock of
DiaMed for approximately 477 million Swiss francs.
-- During the first quarter, the Company introduced a number of new
products including the Mini-PROTEAN® Tetra cell, Bio-Rad's fourth
generation electrophoresis system, and the Profinia(TM) protein
purification system.
-- Also during the quarter, the Company introduced new assays for use on
its BioPlex 2200 system for the detection of the Epstein Barr Virus as well
as three of the most clinically relevant bacteria that cause syphilis.
-- In the second quarter, the Company signed two multi-year agreements
with Quest Diagnostics to place BioPlex 2200 systems and autoimmune test
reagents as well as HIV test systems and quality controls in their network
of reference laboratories nationwide. In addition, Bio-Rad and Beckman
Coulter announced an agreement regarding the continued development and
manufacture of immunodiagnostic tests for blood virus and infectious
disease.
-- In September, the Company introduced three new ProteinChip SELDI
system qualification and calibration kits that help improve reproducibility
during biomarker discovery.
-- In October, Bio-Rad launched the Gene Pulser MXcell(TM)
electroporation system designed for researchers working with mammalian
cells.
-- In November, the Company introduced to the U.S. market, the MRSASelect
test, a chromogenic medium used for the rapid screening of MRSA
(methicillin resistant Staphylococcus aureus).
-- Also in November, Bio-Rad launched the in2it analyzer for the "point-
of-care" diabetes market. The analyzer measures A1C, a well established
indicator of a diabetic patient's glucose control.


Management will discuss these results in a conference call at 2 p.m. Pacific Time (5 p.m. Eastern Time) February 28, 2008. Interested parties can access the call by dialing 800-659-2037 (in the U.S.), or 617-614-2713 (international), access number 75436489. The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 38553576, for seven days following the call and the webcast can be accessed at http://www.bio-rad.com for 30 days.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

http://money.cnn.com/news/newsfeeds/articles/marketwire/0368590.htm
👍️0

Your Recent History

Delayed Upgrade Clock